lisinopril profile

Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5362119
CHEMBL ID	1237
CHEBI ID	43755
SCHEMBL ID	15680
MeSH ID	M0026771
PubMed CID	5362118
CHEMBL ID	419213
CHEBI ID	6503
SCHEMBL ID	542591
MeSH ID	M0026771
PubMed CID	22887897
CHEMBL ID	1729579
SCHEMBL ID	454824
MeSH ID	M0026771

Synonym
BIDD:GT0755
AB00052250-13
BRD-K67966701-335-03-5
AKOS015836369
KBIO1_001037
DIVK1C_001037
coric
doneka
ici-209k
vivatec
longes
carace
acerbon
prinivil
lysinopril
SPECTRUM_000497
zestril
hsdb 6852
lisinopril
PRESTWICK3_000301
PRESTWICK2_000301
SPECTRUM5_000995
BSPBIO_000262
NCGC00179623-01
IDI1_001037
brn 4276619
alapril
presiten
inhibril
l-proline, n2-((1s)-1-carboxy-3-phenylpropyl)-l-lysyl-
noperten
n-(1(s)-carboxy-3-phenylpropyl)-l-lysyl-l-proline
n2-((s)-1-carboxy-3-phenylpropyl)-l-lysyl-l-proline
mk 521
linvas
sinopryl
lipril
tersif
ccris 3568
tensyn
acercomp
cipril
sinopril
lisoril
l-proline, 1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-, (s)-
lispril
linopril
inopril
mk 522
(s)-1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-l-proline
loril
lisipril
cipral
(s)-1-(n2-(1-carboxy-3-phenylpropyl)-l-lysyl)-l-proline
lisinal
novatec
tensopril
lisinoprilum [latin]
prinil
einecs 278-488-1
[n2-[(s)-1-carboxy-3-phenylpropyl]-l-lysyl-l-proline
LPR ,
(s)-1-(n(2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-l-proline
n(2)-[(1s)-1-carboxy-3-phenylpropyl]-l-lysyl-l-proline
76547-98-3
lisinopril anhydrous
CHEBI:43755 ,
DB00722
KBIOSS_000977
KBIO2_000977
KBIOGR_001599
KBIO2_006113
KBIO2_003545
KBIO3_002002
SPBIO_001351
PRESTWICK0_000301
SPECTRUM3_000941
SPECTRUM4_001040
NINDS_001037
SPECTRUM2_001456
SPBIO_002481
PRESTWICK1_000301
SPECTRUM1501217
BPBIO1_000290
smr000544473
MLS001306481
n2-[(1s)-1-carboxy-3-phenylpropyl]-l-lysyl-l-proline
HMS2090O14
HMS2092L21
L0220
1-[nalpha-[(s)-1-carboxy-3-phenylpropyl]-l-lysyl]-l-proline
MLS001306436
nsc-758151
nsc-751176
CHEMBL1237 ,
lisinopril (inn)
D08131
HMS503O15
(2s)-1-[(2s)-6-amino-2-[[(2s)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
HMS1921B14
A838743
(2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenyl-propyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;lisinopril
nsc751176
(s)-1-[n2-(1-carboxy-3-phenylpropyl)-l-lysyl]-l-proline dihydrate
hipril
qbrelis
nsc758151
pharmakon1600-01501217
CCG-39190
77726-95-5
optimon
laaven
lizinopril
lisopril
unii-7q3p4bs2fd
lisinoprilum
listril
skopryl
lisitec
l-proline, 1-(n2-(1-carboxy-3-phenylpropyl)-l-lysyl)-
amicor
1-(n2-(1-carboxy-3-phenylpropyl)-l-lysyl)-l-proline
prinvil
irumed
diroton
l-proline, 1-(n2-(1-carboxy-3-phenylpropyl)-l-lysyl)-, (s)-
7q3p4bs2fd ,
vitopril
lisinopril [inn]
lizonoton
nanopril
BCP9000856
bdbm50367879
HMS2850N20
1-(n(sup 2)-((s)-1-carboxy-3-phenylpropyl)-l-lysyl)-l-proline
lisinopril [who-dd]
lisinopril [mi]
l-proline, 1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-
S2076
AKOS015894970
gtpl6360
n-[n2 -(1(s)-carboxy-3-phenylpropyl)-l-lysyl]-l-proline
n-[n2 (1(s)-carboxy-3-phenylpropyl)-l-lysyl]-l-proline
DL-434
HY-18206
SCHEMBL15680
bdbm66979
(2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenyl-propyl]amino]hexanoyl]proline;hydrate
(2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate
cid_22887897
(2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]-1-oxohexyl]-2-pyrrolidinecarboxylic acid;hydrate
(2s)-1-[(2s)-6-azanyl-2-[[(2s)-1-oxidanyl-1-oxidanylidene-4-phenyl-butan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate
AB00052250_14
AB00052250_15
DTXSID6040537 ,
(2s)-1-[(2s)-6-amino-2-{[(1s)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid
lysinopryl
sr-05000001786
SR-05000001786-1
SBI-0051692.P002
(s)-1-((s)-6-amino-2-(((s)-1-carboxy-3-phenylpropyl)amino)hexanoyl)pyrrolidine-2-carboxylic acid
(s)-1-((s)-6-amino-2-((s)-1-carboxy-3-phenylpropylamino)hexanoyl)pyrrolidine-2-carboxylic acid
n~2~-[(1s)-1-carboxy-3-phenylpropyl]-l-lysyl-l-proline
Q412208
lisinopril (zestril)
(s)-1-[n2-(1-carboxy-3-phenylpropyl)-l-lysyl]-l-proline
(2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
C76449
NCGC00179623-07
lisiprilprinivil
(s)-lisinopril dihydrate
l-proline, n2-[(1s)-1-carboxy-3-phenylpropyl]-l-lysyl-
lisinopril (usp monograph)
dtxcid4020537
n2-((1s)-1-carboxy-3-phenylpropyl)-l-lysyl-l-proline, dihydrate
lisinopril (usp-rs)
rtecs ua0658000
c09aa03
n2-((1s)-1-carboxy-3-phenylpropyl)-l-lysyl-l-proline
lisinoprilum (latin)
n(2)-((1s)-1-carboxy-3-phenylpropyl)-l-lysyl-l-proline
lisinopril (usp impurity)
lisinopril dihydrate (ep monograph)
lisinopril (mart.)
Z1515376765
AC-6226
(s)-lisinopril
(s)-1-(n(2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-l-proline dihydrate
CHEBI:6503 ,
n(2)-[(1s)-1-carboxy-3-phenylpropyl]-l-lysyl-l-proline dihydrate
mk-521
(s)-1-(n2-(1-carboxy-3-phenylpropyl)-l-lysyl)-l-proline dihydrate
renacor
l-proline, 1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-, dihydrate, (s)-
l-proline, 1-(n2-(1-carboxy-3-phenylpropyl)-l-lysyl)-, dihydrate, (s)-
(s)-1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-l-proline dihydrate
1-(n(sup 2)-((s)-1-carboxy-3-phenylpropyl)-l-lysyl)-l-proline dihydrate
PRESTWICK_613
cas-83915-83-7
NCGC00017141-01
lisinopril hydrate (jp17)
prinivil (tn)
lisinopril (usp)
lisinopril dihydrate
D00362
zestril (tn)
HMS1568N04
HMS2095N04
lisinopril hydrate
unii-e7199s1ywr
e7199s1ywr ,
nsc 758151
nsc 751176
lisinopril [usan:usp:inn:ban:jan]
ranolip
CHEMBL419213
dtxsid2045600 ,
dtxcid0025600
tox21_110798
AKOS015950799
lisinopril component of prinzide
lisinopril component of zestoretic
prinzide component lisinopril
lisinopril [mart.]
lisinopril dihydrate [who-dd]
lisinopril [usp-rs]
lisinopril [usan]
lisinopril [orange book]
lisinopril [hsdb]
lisinopril dihydrate [mi]
lisinopril hydrate [jan]
lisinopril [usp impurity]
lisinopril [usp monograph]
lisinopril dihydrate [ep monograph]
zestoretic component lisinopril
CCG-220301
lisinopril (dihydrate)
HY-18206A
SCHEMBL542591
tox21_110798_1
NCGC00179623-04
KS-1078
lisinopril-dihydrat
l-proline, n2-[(1s)-1-carboxy-3-phenylpropyl]-l-lysyl-, dihydrate
lisinopril dihydrate, british pharmacopoeia (bp) reference standard
sr-01000801314
SR-01000801314-3
lisinopril, united states pharmacopeia (usp) reference standard
lisinopril dihydrate, european pharmacopoeia (ep) reference standard
F20515
lisinopril, pharmaceutical secondary standard; certified reference material
lisinopril for system suitability a, european pharmacopoeia (ep) reference standard
lisinopril, >=98% (hplc)
lisinopril for peak identification, european pharmacopoeia (ep) reference standard
lisinopril dihydrate; n2-[(1s)-1-carboxy-3-phenylpropyl]-l-lysyl-l-proline dihydrate; (s)-1-[n2-(1-carboxy-3-phenylpropyl)-l-lysyl]-l-proline dihydrate
HMS3712N04
Q47495698
(s)-1-((s)-6-amino-2-(((s)-1-carboxy-3-phenylpropyl)amino)hexanoyl)pyrrolidine-2-carboxylic acid dihydrate
(s)-1-((s)-6-amino-2-(((s)-1-carboxy-3-phenylpropyl)amino)hexanoyl)pyrrolidine-2-carboxylicaciddihydrate
BL164629
l-proline, n2-[(1s)-1-carboxy-3-phenylpropyl]-l-lysyl-, hydrate (1:2)
(2s)-1-[(2s)-6-amino-2-{[(1s)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid dihydrate
EN300-19652794
smr001233519
MLS002154258 ,
83915-83-7
HMS2230O24
CHEMBL1729579
SCHEMBL454824
mk-521 (dihydrate)
DTXSID30860992
328395-62-6
lisinopril monohydrate

Excerpt	Reference	Relevance
" When patients who received lisinopril or placebo for the same period were compared, the proportion of lisinopril patients reporting an adverse event was 44."	( Safety of long-term use of lisinopril for congestive heart failure. Higgins, TJ; Moyses, C, 1992)	0.28
" Significantly fewer adverse events were experienced on lisinopril and metoprolol than on diuretic treatment."	( Quality of life, side effects and efficacy of lisinopril compared with metoprolol in patients with mild to moderate essential hypertension. Bech, P; Frimodt-Moeller, J; Kornerup, HJ; Poulsen, DL, 1991)	0.28
" In clinical trials, adverse experiences in patients treated with a lisinopril-hydrochlorothiazide combination were dizziness (7."	( Review of international safety data for lisinopril-hydrochlorothiazide combination treatment. Murray, NH, 1991)	0.28
"Data from the lisinopril-captopril comparison trial (6), as well as other data (1, 8, 14, 10) indicate that both long- and short-acting ACEI are effective and safe for the treatment of CHF."	( Comparison of lisinopril and captopril in the treatment of left ventricular congestive heart failure--influence of duration of action on efficacy and safety. Giles, TD, 1991)	0.28
" Treatment was well tolerated and the profile of adverse events was similar to the pattern found with other nonsulfydryl angiotensin converting enzyme inhibitors."	( The antihypertensive effect and safety of lisinopril in patients with mild to moderate essential hypertension. A Belgian multicenter study. De Lame, PA; Droussin, AM; Lame, PA; Thomson, M, 1990)	0.28
" In the hypertensive population, the most frequent clinical adverse experiences on lisinopril alone were headache, dizziness, cough, and diarrhea."	( The safety and tolerability of lisinopril in clinical trials. Merrill, DD; Rush, JE, 1987)	0.27
" It is concluded that lisinopril 5 mg is a safe starting dose for elderly patients who are not on diuretics, and that once-daily lisinopril monotherapy reduces BP safety without affecting heart rate."	( Safety and efficacy of lisinopril in elderly patients with mild to moderate hypertension. De Vriese, G; Marlier, R; Vandepapelière, P, 1989)	0.28
" Here we compare the clinical and laboratory adverse experiences in younger (under 55 years old) and older (at least 55 years old) patients treated with lisinopril monotherapy."	( Safety and tolerability of lisinopril in older hypertensive patients. Lyle, PA; Rush, JE, 1988)	0.27
" There were a total of 35 reported adverse events, 22 of which led to withdrawal of the patient from the study."	( Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trail. Bourge, R; Brozena, SC; Clemson, B; Hobbs, R; Johnson, MR; Miller, L; Mills, RM; Naftel, D; Olivari, MT; Quigg, R; Ventura, H, 1996)	0.29
"These results indicate that both diltiazem and lisinopril are safe for treatment of hypertension after heart transplantation, although titrated monotherapy with either drug controlled the condition in < 50% of patients."	( Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trail. Bourge, R; Brozena, SC; Clemson, B; Hobbs, R; Johnson, MR; Miller, L; Mills, RM; Naftel, D; Olivari, MT; Quigg, R; Ventura, H, 1996)	0.29
" Angiotensin-converting enzyme inhibitors in low dose are a safe and effective long-term therapy for postrenal transplant erythrocytosis."	( Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors. Briggs, JD; Junor, BJ; MacGregor, MS; Rodger, RS; Rowe, PA; Watson, MA, 1996)	0.29
" Adverse events were carefully monitored."	( A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Miller, K; Shahinfar, S; Soffer, B; Vogt, BA; Zhang, Z, 2003)	0.32
" Evaluation of safety of the trial was based on the evaluation of a physician, standard laboratory evaluation, adverse effects."	( Clinical study on safety and efficacy of the administration of amlodipine in a combination with lisinopril in hypertensive patients. Arslanagic, A; Bajraktarevic, A; Zulic, I, 2005)	0.33
" Minor adverse effects have been reported, which were not a reason for interruption of the treatment, with the exception of 3 cases (lower leg oedema, dry cough)."	( Clinical study on safety and efficacy of the administration of amlodipine in a combination with lisinopril in hypertensive patients. Arslanagic, A; Bajraktarevic, A; Zulic, I, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" There was no evidence of dose-related increases in the rate of adverse events with aliskiren treatment."	( Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Calvo, C; Keeling, L; Möckel, V; Satlin, A; Verdecchia, P, 2007)	0.34
"Aliskiren, a novel direct renin inhibitor, provides effective 24-h BP lowering with no evidence of dose-related increases in the incidence of adverse events in elderly patients with hypertension."	( Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Calvo, C; Keeling, L; Möckel, V; Satlin, A; Verdecchia, P, 2007)	0.34
" The main adverse event related to Felodipine was headache, and to Lisinopril was cough."	( [Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China]. Chen, YY; Liu, HL; Shen, FR; Sun, NL; Tao, J; Wu, HY; Xiang, XP; Yu, ZQ; Zhang, FC; Zhang, L; Zhang, WZ; Zhao, JA, 2007)	0.34
"Even in children with mild immunoglobulin (Ig)A nephropathy (IgA-N) showing minimal/focal mesangial proliferation, persistent proteinuria seems to be a risk factor for progression of the disease, indicating the need for an effective and safe treatment even in such cases."	( Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Awazu, M; Hataya, H; Honda, M; Iijima, K; Ishikura, K; Nakanishi, K; Sako, M; Yoshikawa, N, 2009)	0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" She had been treated with quinapril, enalapril, and lisinopril in the past by different primary care physicians without any adverse effects."	( Unique case of presumed lisinopril-induced hepatotoxicity. Adam, AK; Kumar, S; Loe, S; May, EJ; Sethi, S; Shi, D; Tchokonte, R; Zalawadiya, SK, 2010)	0.36
"A woman who had received quinapril, enalapril, and lisinopril in the past without apparent adverse effects developed hepatocellular disease that became evident eight months after lisinopril therapy was reinstituted."	( Unique case of presumed lisinopril-induced hepatotoxicity. Adam, AK; Kumar, S; Loe, S; May, EJ; Sethi, S; Shi, D; Tchokonte, R; Zalawadiya, SK, 2010)	0.36
" Our system employs a sequential, propensity score-matched framework and signalling rules for prospective drug safety monitoring and identified signals for all three adverse drug reactions evaluated."	( Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Avorn, J; Bohn, RL; Daniel, GW; Eisenberg, DF; Gagne, JJ; Patrick, AR; Rassen, JA; Rodgers, JK; Schneeweiss, S; Wahl, PM; Wasser, TE; Wilson, M, 2012)	0.38
" We describe a unique adjunct to standard safety assessment wherein the metabolite profile of treated animals is compared with the MetaMap Tox metabolomics database in order to predict the potential for a wide variety of adverse events, including DIKI."	( Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling. Bush, ED; Fabian, E; Herold, M; Kamp, HG; Krennrich, G; Looser, R; Mattes, WB; Mellert, W; Moeller, N; Nadanaciva, S; Naraoka, H; Omura, K; Piccoli, SP; Prokoudine, A; Ruiz-Noppinger, P; Schuppe-Koistinen, I; Strauss, V; van Ravenzwaay, B; Walk, T, 2013)	0.39
" Propensity scores were generated, and differences in BP and adverse events (angioedema, acute kidney injury, hyperkalemia) between BID/QDay groups were analyzed within dosing cohorts using inverse propensity of treatment-weighted regression models."	( Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. Botts, SR; Delate, T; Derington, CG; Kao, DP; King, JB; Kroehl, M; Trinkley, KE, 2020)	0.56
" No severe adverse effects occurred in the intervention group related to the treatment with lisinopril and bisoprolol."	( The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients. Abdurahman, M; Azhar, Y; Hidayat, S; Wihandono, A, 2021)	0.62

Excerpt	Reference	Relevance
" Pharmacokinetic parameters including area under the serum concentration-time curve (AUC), peak serum concentration (Cmax) and time to peak concentration (tmax), as well as renal function, blood pressure, and plasma renin activity (PRA) and aldosterone levels, were determined on the first and last days of the study."	( Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Cutler, RE; Ford, NF; Parmer, RJ; Sica, DA, 1991)	0.28
"Co-administration of drugs with complementary action is a rational approach to the treatment of hypertension provided that the drugs are free of mutual pharmacokinetic interactions."	( The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. Swaisland, AJ, 1991)	0.28
" Similar differences have been reported for such patient groups when the drugs were administered separately, indicating an absence of pharmacokinetic interaction."	( The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. Connell, PA; Hosie, J; Laher, MS; Mulkerrins, E; Smith, RP; Swaisland, AJ, 1991)	0.28
"The acute hemodynamic, hormonal, and pharmacokinetic aspects of treatment with the angiotensin-converting enzyme (ACE) inhibitor lisinopril were assessed in two studies in 24 patients with chronic stable congestive heart failure (CHF)."	( Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. Dickstein, K, 1987)	0.27
" The influence of renal function and cardiac failure on lisinopril clearance has been confirmed using a population pharmacokinetic analysis technique."	( Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension. Kelly, JG; Thomson, AH; Whiting, B, 1989)	0.28
"In an open, crossover study, the pharmacokinetic and pharmacodynamic profiles of lisinopril and enalapril, administered alone and in combination with propranolol, were evaluated in 12 volunteers."	( Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. Bendtsen, F; Henriksen, JH, 1989)	0.28
"The pharmacokinetic and pharmacodynamic profiles of two angiotensin-converting enzyme (ACE) inhibitors, enalapril (a prodrug) and lisinopril (directly acting), were compared in eight patients with hepatic cirrhosis and 10 healthy controls."	( Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. Bouchier, IA; Hayes, PC; Plevris, JN, 1989)	0.28
"In a pharmacokinetic drug interaction study, the purpose is to determine whether the coadministration of a drug A with a second drug B alters the absorption/distribution/metabolism/elimination profile of either drug."	( The statistical evaluation of a three-period two-treatment crossover pharmacokinetic drug interaction study. Bolognese, JA; Ciminera, JL; Gregg, MH, 1987)	0.27
" Traditionally, separate groups of patients, each with different underlying disease, are given the drug and then detailed studies are performed to assess which groups have significantly different pharmacokinetic parameters and therefore require an adjustment in dose."	( Population pharmacokinetics of lisinopril in hypertensive patients. Thomson, AH; Whiting, B, 1987)	0.27
" In patients with severe renal failure the peak concentrations were higher, the decline in serum concentration was slower and the time to peak concentration was extended."	( Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Geyskes, GG; Porsius, AJ; van der Wouw, PA; van Rooij, HH; van Schaik, BA, 1988)	0.27
" The accumulation half-life averages 12."	( Pharmacokinetics of lisinopril. Beermann, B, 1988)	0.27
" It is therefore possible to study their pharmacokinetics as well as their pharmacodynamic effects in man."	( Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Ajayi, AA; Campbell, BC; Howie, C; Kelman, AW; Meredith, PA; Reid, JL, 1985)	0.27
" After 15 days of lisinopril treatment pharmacokinetic and pharmacodynamic parameters were determined in patients with advanced renal failure (n = 8; endogenous creatinine clearance [CLCR]: 18 ml."	( Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment. Fliser, D; Fliser, M; Mutschler, E; Neubeck, M; Nussberger, J; Pritsch, M; Ritz, E; Weisser, K, 1994)	0.29
"The aim of the present study was to determine whether or not the pharmacokinetic and hemodynamic response to a 20 mg single oral dose of lisinopril was sex-dependent."	( Sex-related pharmacokinetic and pharmacodynamic variations of lisinopril. Barbanoj, M; Bayés, MC; Jané, F; Martín, S; Masana, E; Sáenz-Campos, D, 1996)	0.29
" Based upon this study performed on normal dogs given a single dose, no pharmacokinetic advantage or disadvantage is apparent for any ACEi except captopril, which, at the dosage used, decreased ACE levels to a much lesser degree and shorter time."	( Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. Hamlin, RL; Nakayama, T, )	0.13
" In vehicle-treated SD, SHR and TG+ the half-life (t1/2) of Ang-(1-7) averaged 10+/-1, 10+/-1, and 9+/-1 seconds, respectively."	( Converting enzyme determines plasma clearance of angiotensin-(1-7). Chappell, MC; Ferrario, CM; Ganten, D; Iyer, SN; Yamada, K, 1998)	0.3
" Samples of blood were collected for determination of pharmacokinetic parameters."	( Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Caspi, A; Greenbaum, R; Liao, WC; Mangold, B; Nouriel, H; O'Grady, P; Paz, R; Sclarovsky, S; Yee, KF; Zucchelli, P, 2000)	0.31
" A single 20 mg oral dose of lisinopril was administrated and pharmacokinetic parameters were compared."	( Evaluation of the bioequivalence and pharmacokinetics of two lisinopril tablet formulations after single oral administration in healthy volunteers. Georgarakis, M; Kontopoulos, G; Tsakalof, A; Tsiptsios, I; Zougrou, F, 2004)	0.32
"The pharmacokinetic (PK) parameters of lisinopril were obtained in 46 children aged 6 months to 15 years."	( A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Batisky, DL; Blumer, JL; Delucchi, A; Hand, E; Hogg, RJ; Lo, MW; Panebianco, D; Rippley, R; Sakihara, G; Shahinfar, S; Shaw, W; Tenney, F; Vogt, BA; Wells, TG, 2007)	0.34
" In conclusion, both pharmacodynamic and -kinetic factors account for the non-response to lisinopril."	( Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats. de Zeeuw, D; Henning, RH; Hut, F; Jeronimus-Stratingh, CM; Kluppel, CA; van Dokkum, RP; Windt, WA, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" The primary pharmacodynamic parameters were baseline-adjusted 24-hour mean systolic and diastolic blood pressure."	( The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. Kothare, P; Linnebjerg, H; Mace, K; Mitchell, M; Park, S, 2009)	0.35
" The method described herein was fully validated and successfully applied to the pharmacokinetic study of lisinopril tablets in healthy male volunteers after oral administration."	( Quantitative determination of lisinopril in human plasma by high performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. Jing, L; Li, F; Qin, F; Wang, D; Xiong, Z; Yang, S, 2012)	0.38
"The present study was designed as an open label, multiple-dose, randomized, parallel trial to evaluate the pharmacodynamic drug-drug interaction of lisinopril and concomitantly administered diclofenac sodium in non-diabetic and diabetic, mild to moderate hypertensive, osteoarthritic patients."	( Potential pharmacodynamic drug-drug interaction between concomitantly administered lisinopril and diclofenac sodium: a call for appropriate management in hypertensive osteoarthritic patients. Chudasama, H; Goswami, SK; Jain, S; Santani, D, 2011)	0.37
" This method was successfully applied to a pharmacokinetic study after oral administration of a dose (150 mg) of ranitidine."	( A sensitive and rapid determination of ranitidine in human plasma by HPLC with fluorescence detection and its application for a pharmacokinetic study. Tuncel, M; Ulu, ST, 2012)	0.38
" In this study, we have analysed the ex vivo domain selectivity and pharmacokinetic profile of LisW-S."	( Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. Chibale, K; Davies, NH; Denti, P; Gibhard, L; Kröger, WL; Mahajan, A; Njoroge, M; Schwager, SL; Sharp, SK; Smit, I; Sturrock, ED; Wiesner, L, 2014)	0.4
" We conducted a multicenter, open-label pharmacokinetic (PK) study of daily oral lisinopril in 22 children (ages 7-17 years) with stable kidney transplant function."	( Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection. Anand, R; Feig, DI; Frymoyer, A; Gipson, DS; Goebel, JW; Greenbaum, LA; Lewandowski, A; Lewis, K; Patel, UD; Schwartz, GJ; Trachtman, H; Warady, BA, 2015)	0.42
" A cellular pharmacokinetic model integrating resveratrol transport/metabolism with glucuronide hydrolysis/excretion was well fitted to the experimental data, allowing derivation of the efflux rate constant values in the absence or presence of shRNA targeting MRP4."	( Efflux Transport Characterization of Resveratrol Glucuronides in UDP-Glucuronosyltransferase 1A1 Transfected HeLa Cells: Application of a Cellular Pharmacokinetic Model to Decipher the Contribution of Multidrug Resistance-Associated Protein 4. Dong, D; Li, F; Quan, E; Wang, S; Wu, B, 2016)	0.43
"This study aimed to assess the pediatric lisinopril doses using an adult physiological based pharmacokinetic (PBPK) model."	( Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model. Abbas, N; Arafat, M; Bukhari, NI; Hussain, A; Rashid, M; Rasool, MF; Sadiq, MW; Sarfraz, M, 2020)	0.56
" The findings of previous real time pharmacokinetic studies in pediatric patients supported the present simulated dose."	( Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model. Abbas, N; Arafat, M; Bukhari, NI; Hussain, A; Rashid, M; Rasool, MF; Sadiq, MW; Sarfraz, M, 2020)	0.56

Excerpt	Reference	Relevance
" L/HCTZ appears to be a well-tolerated combination with efficacy on once-daily dosing superior to that of C/HCTZ."	( Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination. Graham, RD, 1991)	0.28
"In an open, crossover study, the pharmacokinetic and pharmacodynamic profiles of lisinopril and enalapril, administered alone and in combination with propranolol, were evaluated in 12 volunteers."	( Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. Bendtsen, F; Henriksen, JH, 1989)	0.28
"The effects on plasma angiotensin-converting enzyme activity and renin activity of the two long-acting angiotensin-converting enzyme inhibitors, lisinopril and enalapril, alone and in combination with propranolol were studied."	( Effects on plasma angiotensin-converting enzyme activity and circulating renin of lisinopril and enalapril alone and in combination with propranolol in healthy volunteers. Bendtsen, F; Hansen, EF; Henriksen, JH, 1999)	0.3
"To compare candesartan cilexetil and lisinopril in fixed combination with hydrochlorothiazide with respect to antihypertensive efficacy and tolerability."	( Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. Istad, H; Keinänen-Kiukaanniemi, S; McInnes, GT; O'Kane, KP; Van Mierlo, HF, 2000)	0.31
" Four variants of the course treatment were used: 1) monotherapy with enalapril maleate (2 mg twice a day); 2) enalapril maleate (5 mg twice a day) in combination with NSAID; 3) monotherapy with lisinopril (10 mg once a day); 4) lisinopril (10 mg once a day in combination with NSAID."	( [Antihypertensive effect of enalapril and lisinopril administered in combination with nonsteroid anti-inflammatory agents]. Brodskaia, SA; Ivanov, SN; Savenkov, MP, 2001)	0.31
" We wished to determine the cardioprotective actions of an aminopeptidase P inhibitor, apstatin alone and in combination with enalapril/lisinopril/ramipril in an in vivo rat model of acute ischemia (30 min) and reperfusion (4 h)."	( Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction. Akula, A; Kota, MK; Routhu, KV; Veeravalli, KK, 2003)	0.32
" Although the participation of the particular transporters in observed drug-drug interactions can be difficult to confirm in humans, this review focuses mainly on pharmacokinetic interactions of clinically important drugs."	( Transporter-mediated Drug Interactions. Tsuji, A, 2002)	0.31
" In this randomized double-blind study we investigated renin-angiotensin system blockade obtained with 3 doses of olmesartan medoxomil (20, 40, and 80 mg every day) in 30 normal subjects and compared it with that obtained with lisinopril alone (20 mg every day) or combined with olmesartan medoxomil (20 or 40 mg)."	( Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Brunner, HR; Burnier, M; Forclaz, A; Hasler, C; Maillard, M; Nussberger, J, 2005)	0.33
" By contrast, renal damage was aggravated when PM was combined with ACEi."	( Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats. Navis, G; van Goor, H; Waanders, F, 2008)	0.35
"In patients with hypertension and metabolic syndrome, manidipine, both alone and in combination with the ACE inhibitor lisinopril, is significantly superior to amlodipine for improving insulin sensitivity as well as several metabolic, inflammatory and prothrombotic markers."	( Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P, 2011)	0.37
"The present study was designed as an open label, multiple-dose, randomized, parallel trial to evaluate the pharmacodynamic drug-drug interaction of lisinopril and concomitantly administered diclofenac sodium in non-diabetic and diabetic, mild to moderate hypertensive, osteoarthritic patients."	( Potential pharmacodynamic drug-drug interaction between concomitantly administered lisinopril and diclofenac sodium: a call for appropriate management in hypertensive osteoarthritic patients. Chudasama, H; Goswami, SK; Jain, S; Santani, D, 2011)	0.37
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"The aim of the study was to estimate the efficacy of lysinopril (and/or its combination with hydrochlorothiazide) in terms of alteration of the diurnal AP profile and heart rhythm in patients with essential hypertension (EH)."	( [The efficacy of lysinopril (and/or its combination with hydrochlorothiazide) in patients with essential hypertension]. Kakhramanova, SM, 2012)	0.38
"In this study we report on potential drug-drug interactions between drugs occurring in patient clinical data."	( Using semantic predications to uncover drug-drug interactions in clinical data. Cairelli, MJ; Fiszman, M; Kilicoglu, H; Melton, GB; Pakhomov, SV; Rindflesch, TC; Rosemblat, G; Zhang, R, 2014)	0.4
" We now investigated the effects of carnosine treatment alone and in combination with ACE inhibition, a clinically established nephroprotective drug in diabetic nephropathy."	( Carnosine treatment in combination with ACE inhibition in diabetic rats. Benck, U; Braunagel, M; Hammes, HP; Hauske, S; Höger, S; Köppel, H; Krämer, BK; Lanthaler, B; Peters, V; Pfister, F; Riedl, E; Schmitt, CP; Yard, BA; Zschocke, J, 2014)	0.4
"Five clinical pharmacology studies evaluated the potential drug-drug interaction between multiple subcutaneous taspoglutide doses and a single dose of lisinopril, warfarin, and simvastatin and multiple doses of digoxin and an oral contraceptive containing ethinylestradiol and levonorgestrel."	( Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. Bogman, K; Brumm, J; Giraudon, M; Hofmann, C; Mangold, B; Niggli, M; Sauter, A; Schmitt, C; Sturm, S; Sturm-Pellanda, C, 2019)	0.51
" Participants were divided into six treatment groups based on the hypertensive drug therapy they were using; lisinopril, losartan or valsartan alone or in combination with hydrochlorothiazide (A, B and C group respectively) or combination of lisinopril, losartan or valsartan with/without hydrochlorothiazide together with amlodipine (D, E and F respectively)."	( Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. Hebibovic, S; Jatic, Z; Rustempasic, E; Skopljak, A; Sukalo, A; Valjevac, A, 2019)	0.51
"These data suggest that lisinopril/lisinopril + hydrochlorothiazide, losartan/losartan + hydrochlorothiazide and valsartan/valsartan + hydrochlorothiazide alone or in combination with amlodipine are equally effective and well tolerated for the reduction of both systolic and diastolic blood pressure and improve arterial stiffness in patients with essential hypertension."	( Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. Hebibovic, S; Jatic, Z; Rustempasic, E; Skopljak, A; Sukalo, A; Valjevac, A, 2019)	0.51
"This study aimed to estimate how prevalent potential drug-drug interactions (pDDIs) were in patients with cardiovascular diseases who were hospitalized for more than 24 hours, and to determine the risk factors associated with these pDDIs."	( Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital. Almaghaslah, D; Khaled, A; Makki, S; Nagib, R; Siddiqua, A, 2023)	0.91

Excerpt	Reference	Relevance
" This apparent tissue selectivity may stem from either differences in tissue bioavailability or from a different affinity for the enzyme."	( Differences in structure of angiotensin-converting enzyme inhibitors might predict differences in action. Herman, AG, 1992)	0.28
" Lisinopril bioavailability (approximately 25%) is not significantly affected by food, age, or coadministration of hydrochlorothiazide (HCTZ), propranolol, digoxin, and glibenclamide."	( The clinical pharmacology of lisinopril. Cirillo, VJ; Gomez, HJ; Moncloa, F, 1987)	0.27
" Its bioavailability is approximately 25% and is not affected by food."	( Lisinopril: a new angiotensin-converting enzyme inhibitor. Chase, SL; Sutton, JD, 1989)	0.28
" Although hydralazine had no effect on the bioavailability of enalapril, significantly increased bioavailability was observed with lisinopril."	( Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. Drummer, OH; Froomes, P; McLean, AJ; McNeil, JJ; Smith, HJ, 1989)	0.28
" Compound 2 is well absorbed from rat jejunum, whereas lisinopril absorption is relatively low."	( Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. Amidon, GL; Friedman, DI, 1989)	0.28
"The angiotensin-converting enzyme inhibitor, lisinopril, has an oral bioavailability of 25 percent +/- 4 percent, which is unaffected by food."	( Pharmacokinetics of lisinopril. Beermann, B, 1988)	0.27
" Although there were no statistically significant differences in lisinopril pharmacokinetics during single or combined treatment, serum and urinary parameters suggest that bioavailability may be enhanced slightly during combined treatment."	( A study of the potential pharmacokinetic interaction of lisinopril and digoxin in normal volunteers. Dews, IM; Kelly, JG; Marks, C; Morris, F; Stephens, JD; Vandenburg, MJ, 1988)	0.27
" A population pharmacokinetic analysis approach applied to a few concentration-time data points in each of a relatively large number of subjects provided average population parameter estimates of the absorption rate constant, volume of distribution and clearance which correspond closely with the limited published data based on conventional pharmacokinetic approaches."	( Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Ajayi, AA; Campbell, BC; Howie, C; Kelman, AW; Meredith, PA; Reid, JL, 1985)	0.27
"A randomized, two-way, crossover study was performed on 18 normal volunteers to assess the influence of food on the bioavailability of lisinopril, (1-[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline), a long-acting nonsulfhydryl angiotensin converting enzyme inhibitor."	( Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. Clementi, RA; Ferguson, RK; Hoholick, C; Mojaverian, P; Rocci, ML; Vlasses, PH, 1986)	0.27
"The aim of the present studies, performed in two different groups of volunteers, was to compare the bioavailability of 20 mg lisinopril tablets (Sinopryl as test and an orignator product as reference formulation; study 1) and lisinopril/hydrochlorothiazide (20 mg/12."	( Effect of the combination of lisinopril and hydrochlorothiazide on the bioequivalence of tablet formulations. Alpan, RS; Erenmemisoglu, A; Koytchev, R; Ozalp, Y; van der Meer, MJ, 2004)	0.32
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."	( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010)	0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
"Angiotensin-converting enzyme (ACE) inhibitors differ in their lipophilic/hydrophilic index that determines their tissue bioavailability and affinity to ACE, which may result in major differences in the degree of blockade of cardiac ACE."	( Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE". Coletta, E; Davies, R; Haddad, H; Leenen, FH; Ruzicka, M; White, R, 2010)	0.36
" The bioavailability of compound 4j was determined in experimental mice."	( Design, synthesis, and antihypertensive activity of curcumin-inspired compounds via ACE inhibition and vasodilation, along with a bioavailability study for possible benefit in cardiovascular diseases. Dong, XB; Du, ZM; Guo, Y; Hu, X; Liao, LZ; Liao, XX; Wang, LC; Zhuang, XD, 2016)	0.43
" These results suggest that the extent of intestinal absorption of lisinopril was significantly impaired in the presence of GTE, whereas it had no major effect on the absorption rate and renal excretion of lisinopril."	( Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers. Abe, O; Misaka, S; Ogata, H; Ono, T; Ono, Y; Onoue, S; Sato, H; Shikama, Y; Shimomura, K; Suzuki, M; Uchida, A, 2021)	0.62
" This finding was concurrent with significantly increased serum bioavailability of nitric oxide in the hypertensive rats treated with L-arginine and lisinopril."	( L-arginine and lisinopril supplementation protects against sodium fluoride-induced nephrotoxicity and hypertension by suppressing mineralocorticoid receptor and angiotensin-converting enzyme 3 activity. Adedapo, AA; Adedapo, AD; Adejumobi, OA; Adetona, MO; Ajibade, TO; Aro, AO; Awodele, OA; Kayoka-Kabongo, PN; McGaw, LJ; Nkadimeng, SM; Oguntibeju, OO; Ola-Davies, OE; Omobowale, TO; Oyagbemi, AA; Saba, AB; Tijani, MO; Yakubu, MA, 2023)	0.91
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" It remains to be documented whether the persistence and degree of ACE inhibition is a factor in this effect, and, thus, comparison of short- with long-acting ACE inhibitors and study of the dosage of ACE inhibitors are of importance."	( Angiotensin-converting enzyme inhibition, the sympathetic nervous system, and congestive heart failure. The Australian Zestril (Lisinopril) Study Group. Sloman, G, 1992)	0.28
"01) from baseline over the 24 h dosing interval."	( Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. Dunne, B; Glazer, N; Kostis, JB; Miller, WE; Rector, DJ; Tresznewsky, ON; Whelton, A, 1992)	0.28
" This reaction to ACE inhibitors appears to be dose related, and subsides with a decreased dosage or discontinuation of the medication."	( Lisinopril-induced "scalded mouth syndrome". Haushalter, NM; Savino, LB, 1992)	0.28
" In order to investigate whether there is a causal relationship between plasminogen-activator activity and smooth muscle cell migration, animals were dosed with tranexamic acid."	( The role of plasminogen activation in smooth muscle cell migration after arterial injury. Jackson, CL; Reidy, MA, 1992)	0.28
" After a 2 week placebo, the examinees were administered either L in increasing dose of 10, 20, or 40 mg per day (amount necessary to achieve normotension), or C in a dosage of 25, 50, or 100 mg per day."	( [Comparison of captopril and lisinopril in the treatment of mild and moderate hypertension]. Janezic, A; Knezević, S; Lijić, J; Marinković, M; Rumboldt, Z; Simunić, M, )	0.13
" An evaluation of reduction in blood pressure, and of response rate and side-effects suggests that an initial dose of 10 mg lisinopril once daily is sufficient, and that this dosage will control blood pressure in the majority of patients."	( [Treatment of hypertension with the ACE inhibitor lisinopril. A multicenter study of patients with mild to moderate hypertension in general practice]. Fagerthun, HE; Landmark, K; Larsen, S; Tellnes, G, 1991)	0.28
" L/HCTZ appears to be a well-tolerated combination with efficacy on once-daily dosing superior to that of C/HCTZ."	( Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination. Graham, RD, 1991)	0.28
" Dosing with hydrochlorothiazide alone resulted in a mean peak serum concentration of 53 ng/ml, 2-6 hours post dose."	( The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. Swaisland, AJ, 1991)	0.28
" The pharmacokinetic behaviour of lisinopril and hydrochlorothiazide given together to elderly and renally impaired hypertensive patients suggests that a fixed dose combination is appropriate and that no changes to the dosage regimen additional to those used for the individual agents are necessary."	( The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. Connell, PA; Hosie, J; Laher, MS; Mulkerrins, E; Smith, RP; Swaisland, AJ, 1991)	0.28
" During consecutive dosing of lisinopril, its antihypertensive effects were sustained for greater than or equal to 12 h with less diurnal variation of BP."	( Pharmacokinetics and antihypertensive effects of lisinopril in hypertensive patients with normal and impaired renal function. Abe, Y; Ebina, T; Gotoh, E; Ishii, M; Matsukawa, T; Minamisawa, K; Shionoiri, H; Sugimoto, K; Ueda, S, 1990)	0.28
" For the 47 patients randomized, data were collected for 25 patients switched to an equal milligram dosage of lisinopril and for 21 patients who continued to receive a constant dosage of enalapril."	( Cost of switching hypertensive patients from enalapril maleate to lisinopril. Goodfriend, TL; Lindgren-Furmaga, EM; Schuna, AA; Wolff, NL, 1991)	0.28
" The dose should be adjusted to the pretreatment GFR, and a decrease in dosage should be considered with prolonged treatment."	( Lisinopril in hypertensive patients with renal function impairment. Apperloo, AJ; de Jong, PE; de Zeeuw, D; Heeg, JE, 1990)	0.28
" A similar elimination profile was observed when the compound was dosed in its active form (FPL 63547 diacid), 87."	( Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. Carr, RD; Cooper, AE; Hutchinson, R; Mann, J; O'Connor, SE; Robinson, DH; Wells, E, 1990)	0.28
" Lisinopril seems to be at least as effective as captopril in congestive heart failure, and it has over the latter the advantage of a once a day dosage therapy."	( [The value of lysinopril in cardiac insufficiency]. Lambert, M; Luccioni, R, 1990)	0.28
" Arterial blood pressure was monitored continuously for 6 h following each dosage using an intraarterial cannula."	( Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. Dickstein, K, 1987)	0.27
" After a 2-week run-in period, 130 patients receiving digoxin and/or diuretics were randomised to 12 weeks of treatment with lisinopril 5 mg daily (87 patients) or with placebo (43 patients), with an option to increase lisinopril dosage to 10 or 20 mg."	( Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. Chalmers, JP; Cyran, J; De La Torre, D; Englert, M; Kramar, M; Lewis, GR; Maranhao, MF; Myburgh, DP; Schuster, P; West, MJ, 1987)	0.27
"5 mg orally, was given every 24 h initially; in six patients, dosage was decreased to an alternate or once-a-week schedule, because of a hypotensive effect during dialysis."	( Treatment of hypertension with lisinopril in end-stage renal failure. Bellucci, A; Küntziger, HE; Pouthier, D, 1987)	0.27
" A dose-response relation for most parameters was noted."	( Lisinopril for severe congestive heart failure. Amin, D; LeJemtel, T; Levine, TB; Liang, CS; Linnemaier, T; Shah, PK; Shaver, JA; Uretsky, BF; Walinsky, P, 1989)	0.28
" After 12 weeks of therapy with lisinopril, the dosage of which was titrated to produce optimal relief of symptoms of congestive heart failure (CHF), repeat hemodynamic studies revealed persistent significant reductions in baseline systemic arterial pressure, pulmonary artery wedge pressure, mean pulmonary arterial pressure and systemic vascular resistance."	( Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Amin, DK; Langendörfer, A; Liang, CS; Linnemeier, TJ; Rush, JE; Shah, PK; Snapinn, SM; Stone, CK; Uretsky, BF, 1989)	0.28
" The usual initial oral dosage of lisinopril is 10 mg once a day (range 20-40 mg/day)."	( Lisinopril: a new angiotensin-converting enzyme inhibitor. Chase, SL; Sutton, JD, 1989)	0.28
" Lisinopril treatment reduced supine and standing cuff clinic measurements of BP 24 h after dosing by (systolic/diastolic) 21."	( Assessment of the antihypertensive effect of lisinopril using 24-hour ambulatory monitoring. Conte, D; Herpin, D, 1989)	0.28
" These properties are consistent with once-daily dosing and uncomplicated clinical use in the treatment of hypertension and congestive heart failure."	( The clinical pharmacology of lisinopril. Case, DE, 1989)	0.28
" There was a linear dose-response relationship for both supine and erect blood pressure."	( Lisinopril dose-response relationship in essential hypertension. Chrysant, SG; Cirillo, VJ; Gomez, HJ; Gradman, AH; Leon, AS; MacCarthy, EP; Otterbein, ES; Rush, JE; Shaw, WC; Sromovsky, JA, 1989)	0.28
" In ex vivo dose-response and time-course studies, the inhibitory effects of the seven drugs on tissue ACEs and their relative distributions to SHR tissues were compared following oral administration."	( Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Cushman, DW; DeForrest, JM; Fung, WC; Grover, GJ; Harvey, CM; Mitch, SL; Scalese, RJ; Wang, FL, 1989)	0.28
"If optimal dosage administration schedules are to be defined, the factors that influence the disposition of a drug in the population of patients who are likely to receive it should first be determined."	( Population pharmacokinetics of lisinopril in hypertensive patients. Thomson, AH; Whiting, B, 1987)	0.27
" The dosage of lisinopril was titrated upward to 40 mg daily according to BP response."	( Lisinopril treatment of hypertension in patients with impaired renal function. Cooper, WD; Donohoe, JF; Doyle, GD; Glover, DR; Laher, M; Long, C, 1987)	0.27
" Prolonged duration of action of lisinopril allows once daily dosing, unlike captopril for which dosing is required every 8-12 hours or enalapril which may necessitate twice daily dosing."	( Lisinopril: a new angiotensin-converting enzyme inhibitor. Armayor, GM; Lopez, LM, 1988)	0.27
" The changes were present up to 24 hours after dosing for most parameters."	( Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses Amin, D; LeJemtel, T; Levine, TB; Liang, CS; Linnemeier, T; Rush, JE; Shah, PK; Shaver, JA; Uretsky, BF; Walinsky, P, 1988)	0.27
" Lisinopril reduced systolic blood pressure and inhibited serum ACE activity in both normal and diabetic rats in a dose-response fashion."	( Effects of the angiotensin converting enzyme inhibitor, lisinopril, on normal and diabetic rats. Hartmann, JF; Hayes, NS; Keegan, ME; Slater, EE; Szemplinski, M, 1988)	0.27
"The chemistry, pharmacology, pharmacokinetics, clinical use, adverse effects, and dosage of lisinopril are reviewed."	( Lisinopril: a nonsulfhydryl angiotensin-converting enzyme inhibitor. Murray, KM; Noble, TA, 1988)	0.27
" The design of dosage regimens of both lisinopril and enalapril for patients with severe renal impairment or chronic renal failure should take into consideration the use and effects of haemodialysis."	( Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. Carmody, M; Cooper, WD; Doyle, GD; Glover, DR; Kelly, JG, 1988)	0.27
" Both drugs reduced blood pressure without change in heart rate after acute dosing and after seven days."	( Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man. Ajayi, AA; Campbell, BC; Howie, CA; Reid, JL, 1985)	0.27
" Population drug concentration data obtained in the course of early clinical evaluations of new drugs may provide a rational basis for dosage regimens with improved efficacy and, in particular, reduced concentration-related toxic effects."	( Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Ajayi, AA; Campbell, BC; Howie, C; Kelman, AW; Meredith, PA; Reid, JL, 1985)	0.27
" In patients with severe renal failure, adjustment of the dose or the dosing frequency to the degree of renal failure is recommended to avoid administration of doses in excess of those required to achieve adequate inhibition of converting enzyme."	( Lisinopril in hypertensive patients with and without renal failure. Boer, P; Geyskes, GG; van Schaik, BA, 1987)	0.27
" Serum profiles after chronic dosing of enalapril show little accumulation of the active diacid metabolite, enalaprilat."	( Kinetic and metabolic aspects of enalapril action. Lant, AF; McNabb, RW; Noormohamed, FH, 1984)	0.27
" All patients were New York Heart Association Functional Class II, III, or IV and had remained symptomatic despite optimal dosing with digoxin and diuretics."	( Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group. Beller, B; Bourge, RC; Bulle, T; Colfer, H; Fisher, MB; Fowles, RE; Giles, TD; Grover, J; Jessup, M; Whipple, JP, 1995)	0.29
" At the end of both periods, sphygmomanometric blood pressure was assessed 24 hours after dosing and 24-hour ambulatory blood pressure was performed, taking blood pressure readings every 15 minutes during day- and night-time."	( [The antihypertensive effects of the lisinopril-hydrochlorothiazide combination (Zestoretic) in elderly hypertensive patients. The results of a multicenter study. The Italian Zestoretic Study Group]. Mancia, G, 1994)	0.29
" However, the search for the optimal dosage was not undertaken in these trials (a standard dose was fixed at the onset, average dose of enalapril from 15 to 20 mg/day)."	( [The ATLAS study (Assessment of Treatment with Lisinopril and Survival); justification and objectives]. Komajda, M; Thibout, E; Wimart, MC, 1994)	0.29
" The differences were most marked 19-24 hours post dosage time when pressures (systolic/diastolic) during lisinopril therapy were lower than during captopril by 18."	( Once daily lisinopril and captopril in hypertension: a double blind comparison using ambulatory monitoring. Mann, S; O'Brien, KP, 1994)	0.29
"In this study, lisinopril proved a more effective once daily antihypertensive agent than captopril, especially in the last 6 hours of the 24-hour dosage interval."	( Once daily lisinopril and captopril in hypertension: a double blind comparison using ambulatory monitoring. Mann, S; O'Brien, KP, 1994)	0.29
" Significantly more patients were dosed on a twice daily regimen of enalapril than lisinopril."	( A multi-center analysis of the use of enalapril and lisinopril in elderly hypertensive patients. Cotsonis, G; Douglas, MB; Hall, WD; Hawkins, DW, 1994)	0.29
" Evaluation criteria were efficacy, clinical experience, safety, dosage interval, hepatic bioactivation, interactions, dosage forms and cost."	( Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors. Atienza Fernández, M; Carvajal Gragera, E; Piña Vera, MJ; Santos Ramos, B, 1993)	0.29
" Increases in dosage caused very little increase in haemodynamic effect, suggesting that complete suppression of the angiotensin-converting enzyme may not be necessary for an optimal clinical response."	( Acute haemodynamic effects of lisinopril and captopril in patients with severe congestive heart failure. Byttebier, G; Van Hedent, T; Van Mieghem, W, 1993)	0.29
"05) shifted the dose-response relationship of ammonium persulfate-induced reduction in cardiac contractile frequency."	( Lisinopril increases the recovery during reoxygenation and resistance to oxidative damage in cardiomyocytes. Rabkin, SW, 1993)	0.29
" On the other hand, both, systolic and diastolic blood pressure decreased satisfactory during the night with the dosage received in the morning."	( [The antihypertensive effect of lisinopril in a single daily dosage. A study of arterial pressure with ambulatory monitoring]. Galván Montiel, O; González Romero, S; Guadalajara Boo, JF, )	0.13
"This study examined the effects of lisinopril on diastolic function in 12 normotensive patients (mean age 72 years) with symptomatic congestive heart failure, intact left ventricular systolic function and abnormal diastolic function secondary to ischaemic heart disease in a placebo-controlled double blind crossover study, with each treatment dosed orally for 5 continuous weeks."	( Effects of lisinopril on congestive heart failure in normotensive patients with diastolic dysfunction but intact systolic function. Kennedy, N; Lang, CC; Lipworth, BJ; McAlpine, HM; Rahman, AR; Struthers, AD, 1995)	0.29
"To provide clinical support that conversion from captopril to lisinopril at a daily oral dosage ratio of 5:1 maintains comparable therapeutic efficacy, and to estimate retrospectively cost savings because of conversion from captopril to lisinopril therapy at the study site and with the associated overall drug conversion program instituted by Kaiser Permanente."	( Conversions from captopril to lisinopril at a dosage ratio of 5:1 result in comparable control of hypertension. Gill, TH; Hauter, F; Pelter, MA, 1996)	0.29
"The blood pressures of patients in whom captopril therapy was switched to lisinopril therapy were maintained throughout the entire study within the defined acceptable limits of control when the conversion was initiated at a daily oral dosage ratio of 5:1."	( Conversions from captopril to lisinopril at a dosage ratio of 5:1 result in comparable control of hypertension. Gill, TH; Hauter, F; Pelter, MA, 1996)	0.29
"The conversion from captopril (in equally divided daily doses) to lisinopril (once daily) at a dosage ratio of 5:1 maintained comparable control of mild-to-moderate hypertension with no increase in adverse effects."	( Conversions from captopril to lisinopril at a dosage ratio of 5:1 result in comparable control of hypertension. Gill, TH; Hauter, F; Pelter, MA, 1996)	0.29
" An incremental dose-response effect was observed both in clinic and ambulatory blood pressure parameters during treatment with mibefradil and nifedipine GITS alone and combined with lisinopril."	( The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. Archambault, F; Dalle Ave, S; Lacourcière, Y; Lefebvre, J; Lindberg, E; Poirier, L; Ward, C, 1997)	0.3
" The renal dysfunction induced by simultaneous administration of lisinopril with PAN could be abolished by combination dosing with sarcosine, an angiotensin II (AII)-receptor agonist."	( Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats. Kurihara, H; Shinosaki, T; Sunagawa, N; Takagawa, I; Yonetani, Y, 1997)	0.3
" Significant dose-response differences were observed between treatments."	( Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Anzalone, DA; Falkner, B; Hutchinson, HG; Reisin, E; Tuck, ML; Weir, MR, 1997)	0.3
"5 mg combination is more effective during the last period of the dosing interval."	( [Comparison of antihypertensive and metabolic effects of lisinopril 20 mg/hydrochlorothiazide 12.5 mg fixed combination and captopril 50 mg/hydrochlorothiazide 25 mg fixed combination]. Baleydier, A; Milon, H, )	0.13
"Thirty THM aged 12 weeks were distributed equally to a lisinopril dosage group, a hydralazine dosage group, and an untreated group."	( Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice. Fukamizu, A; Ishikawa, K; Kai, T; Kurooka, A; Murakami, K; Shimada, S; Sugimura, K; Takenaka, T, 1998)	0.3
" Dosage could be increased for both telmisartan (40 --> 80 --> 160 mg) and lisinopril (10 --> 20 --> 40 mg) at each of the first 2 monthly visits if DBP control (<90 mm Hg) had not been established."	( Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Frishman, WH; Guthrie, G; Neutel, JM; Oparil, S; Papademitriou, V, 1999)	0.3
" Vasoconstriction was induced by epinephrine in all groups in a dose-response fashion."	( Vascular effects of epinephrine, lisinopril, and chlorpromazine in diabetic and non-diabetic rats. Aygit, AC; Ayhan, MS; Demiralay, A; Yildirim, I, 1999)	0.3
"To compare the serum pharmacokinetics of fosinoprilat with enalaprilat and lisinopril after 1 and 10 days of dosing with fosinopril, enalapril and lisinopril."	( Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Caspi, A; Greenbaum, R; Liao, WC; Mangold, B; Nouriel, H; O'Grady, P; Paz, R; Sclarovsky, S; Yee, KF; Zucchelli, P, 2000)	0.31
" The proposed methods proved to be suitable for a rapid quality control of commercial dosage forms."	( Spectrophotometric and spectrofluorometric methods for the assay of lisinopril in single and multicomponent pharmaceutical dosage forms. Abdine, HH; El-Yazbi, FA; Shaalan, RA, 1999)	0.3
"To be listed for heart transplantation (HTx), optimization of the dosage of angiotensin converting enzyme (ACE) -inhibitors is recommended worldwide even though this issue has not been thoroughly investigated in the pre-transplantation cohort."	( ACE inhibitor dosage at the time of listing predicts survival. Berger, R; Frey, B; Kozanly, I; Kuchling, G; Pacher, R; Stanek, B, 2000)	0.31
" Earlier studies combining short acting drugs from these classes require multiple dosing and were associated with poor compliance."	( Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension. Naidu, MU; Rao, TR; Shobha, JC; Usha, PR, 2000)	0.31
" Single-dose combination antihypertension therapy is an important option that combines efficacy of blood pressure reduction and a low side effect profile with convenient once-daily dosing to enhance compliance."	( Combination antihypertensive drugs: recommendations for use. Beck, JD; Clark, M; Skolnik, NS, 2000)	0.31
" In conclusion, this reappraisal of the conflicting observations reported on ACE inhibitor effects on exercise capacity has highlighted a proposition that there is an optimal dosage of ACE inhibitors which will most enhance exercise capacity, and this will require further well designed cross-over studies to elucidate."	( Disparate results of ACE inhibitor dosage on exercise capacity in heart failure: a reappraisal of vasodilator therapy and study design. Cooke, GA; Tan, LB; Williams, SG; Wright, DJ, 2001)	0.31
"We sought to describe the dosages of angiotensin-converting enzyme (ACE) inhibitor prescribed to elderly patients with heart failure at hospital discharge, the factors associated with dosing level, and the association of these dosages with 1-year outcomes."	( Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Chen, YT; Krumholz, HM; Radford, MJ; Wang, Y, 2001)	0.31
" We observed a dose-response relationship between higher doses and lower mortality."	( Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Chen, YT; Krumholz, HM; Radford, MJ; Wang, Y, 2001)	0.31
" On the basis of the ambulatory blood pressure monitoring (ABPM) studies, it has been previously demonstrated that the antihypertensive effect of once daily drug, generally administrated in the morning, decreases at the end of the dosing period."	( Management of antihypertensive treatment with Lisinopril: a chronotherapeutic approach. Macchiarulo, C; Mitolo, DC; Pieri, R; Pirrelli, A, )	0.13
" In contrast, urinary excretion rates of Ang I and Ang-(1-7) but not Ang II increased significantly throughout the dosing period of subjects who were given omapatrilat, whereas the smaller antihypertensive response produced by lisinopril had a smaller and transient effect on increasing urinary excretion rates of Ang-(1-7)."	( Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Brosnihan, B; Campese, VM; Chappell, MC; Ferrario, CM; Grim, CE; Liao, WC; Ruddy, MC; Smith, RD; Vesterqvist, O, 2002)	0.31
" Telmisartan (40, 80, and 120 mg) provided greater decreases in mean hourly systolic and diastolic blood pressure throughout the 24-hour dosing interval, including the last 4 hours of the dosing period, than amlodipine (5 and 10 mg)."	( Comparative effects of telmisartan in the treatment of hypertension. White, WB, )	0.13
"The aerobic exercise capacity (primary end-point) was significantly higher during the 5mg per day dosage compared to the 20 mg (1696 vs 1578 ml."	( A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients. Al-Timman, JK; Cooke, GA; Marshall, P; Shelbourne, J; Tan, LB; Williams, SG; Wright, DJ, 2002)	0.31
"5 mg) were evaluated for bioequivalence after single dosing in healthy volunteers."	( Comparative bioavailability of two immediate-release tablets of lisinopril/hydrochlorothiazide in healthy volunteers. Cuadrado, A; Dalmau, R; Gascón, AR; Hernández, RM; Pedraz, JL; Ramírez, E; Solinís, MA, 2003)	0.32
"This study explored the dose-response relationship and safety of lisinopril in 115 hypertensive children, aged 6 to 16 years."	( A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Miller, K; Shahinfar, S; Soffer, B; Vogt, BA; Zhang, Z, 2003)	0.32
"There was a dose-response relationship between the lowest and each of the higher doses of lisinopril."	( A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Miller, K; Shahinfar, S; Soffer, B; Vogt, BA; Zhang, Z, 2003)	0.32
"As the results of the Heart Outcomes Prevention Evaluation trial suggested that patients with both coronary artery disease (CAD) and diabetes mellitus would benefit from angiotensin-converting enzyme (ACE) inhibitor therapy, our objective was to increase the percentage of patients with both of these conditions receiving the goal dosage (20 mg/day) or highest tolerated dosage of the ACE inhibitor lisinopril through intervention of a clinical pharmacy service."	( Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus. Humphries, TL; McConnell, KJ; Merenich, JA; Raebel, MA, 2003)	0.32
"At hospital discharge, lisinopril 5 mg/day was started in eligible patients; the drug was titrated to a goal dosage of 20 mg/day or the highest tolerated dosage."	( Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus. Humphries, TL; McConnell, KJ; Merenich, JA; Raebel, MA, 2003)	0.32
"The clinical pharmacy service more than doubled the number of patients with CAD and diabetes who achieved the goal dosage of an ACE inhibitor, a drug class that has been shown to decrease morbidity and mortality in this patient population."	( Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus. Humphries, TL; McConnell, KJ; Merenich, JA; Raebel, MA, 2003)	0.32
" Increased ANP mRNA expression following doxorubicin dosing was localized predominantly in ventricular myocytes by in situ hybridization."	( Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Atkinson, J; Boucek, RJ; Miracle, A; Steele, A, 2003)	0.32
"Two sensitive, simple and specific methods based on spectrophotometry and reversed-phase HPLC with fluorimetric detection are described for the determination of lisinopril in dosage forms as well as in spiked human plasma using solid phase extraction (SPE) procedures."	( Determination of lisinopril in dosage forms and spiked human plasma through derivatization with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) followed by spectrophotometry or HPLC with fluorimetric detection. El-Ashry, SM; El-Emam, AA; El-Sherbiny, DT; Hansen, SH; Moustafa, MA, 2004)	0.32
" Little is known about the stability of lisinopril in extemporaneously prepared liquid dosage forms."	( Stability of lisinopril in two liquid dosage forms. Morosco, RS; Nahata, MC, 2004)	0.32
"Lisinopril can be prepared in either of 2 liquid dosage forms and stored for at least 13 weeks under refrigeration and 8 weeks at room temperature."	( Stability of lisinopril in two liquid dosage forms. Morosco, RS; Nahata, MC, 2004)	0.32
" The aim of the study was to investigate dosing of ACE inhibitors in patients discharged from the hospital after an acute myocardial infarction (AMI) and, furthermore, to compare these doses with the doses actually reached in clinical trials."	( The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction. Kvan, E; Reikvam, A, 2004)	0.32
" Outcome variables, including deaths and drug utilization with dosing after 6 months, were collected."	( The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction. Kvan, E; Reikvam, A, 2004)	0.32
" Both the methods have been applied to the determination of lisinopril in pharmaceutical dosage forms."	( Application of pi-acceptors to the spectrophotometric determination of lisinopril in commercial dosage forms. Anwar, N; Kashif, M; Rahman, N, )	0.13
" With a daily dosing regime, systolic BP, mean arterial pressure (MAP), diastolic BP, and pulse pressure (PP) were significantly lower in the lisinopril group compared to the placebo group at day 14 (P < ."	( Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up. Eveson, DJ; Potter, JF; Robinson, TG, 2007)	0.34
" Whether these can be overcome simply by increasing drug dosage in non-responders should be investigated."	( Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats. de Zeeuw, D; Henning, RH; Hut, F; Jeronimus-Stratingh, CM; Kluppel, CA; van Dokkum, RP; Windt, WA, 2008)	0.35
" We can conclude that the results obtained in this study support an option of tablet splitting, which is very important for obtaining the required dosage when a dosage form of the required strength is unavailable, and for better individualization of the therapy."	( Influence of tablet splitting on content uniformity of lisinopril/hydrochlorthiazide tablets. Uzunović, A; Vranić, E, 2007)	0.34
"Tablets are one of the most popular and preferred solid dosage forms because they can be accurately dosed, easily manufactured and packaged on a large scale, have good physical and chemical stability, and can contribute to good patient compliance given their ease of administration."	( Comparison of some physical parameters of whole and scored lisinopril and lisinopril/hydrochlorthiazide tablets. Uzunović, A; Vranić, E, 2008)	0.35
" Exenatide delayed the time to attain maximum lisinopril concentration (tmax,ss) by 2 hours but did not significantly alter maximum lisinopril concentration (Cmax,ss) or area under the concentration-time profile (AUCtau,ss) over the 24-hour steady-state dosing interval."	( The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. Kothare, P; Linnebjerg, H; Mace, K; Mitchell, M; Park, S, 2009)	0.35
"We obtained dose-response curve for the administration of complete extract and extract fractions."	( Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism. Badillo, FH; González-Cortazar, M; Herrera-Ruiz, M; Jiménez-Ferrer, E; Tortoriello, J, 2010)	0.36
" Spearman correlation analyses indicated an inverse relationship between lisinopril dosage and number of polyps (P<0."	( Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. Cipher, D; Kedika, R; Mahgoub, A; Patel, M; Pena Sahdala, HN; Siddiqui, AA, 2011)	0.37
" This study's purpose was to determine whether an antihypertensive regimen including a maximally dosed angiotensin-converting enzyme inhibitor could safely achieve target BP in indigent, predominantly minority patients with this disease."	( Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Adams-Huet, B; Toto, RD; Van Buren, PN, 2010)	0.36
"A regimen using a maximally dosed angiotensin-converting enzyme inhibitor is safe and effective for achieving BP goal in high-risk, predominantly minority patients with diabetic nephropathy."	( Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Adams-Huet, B; Toto, RD; Van Buren, PN, 2010)	0.36
" When the dosage of prednisone was reduced, symptoms returned."	( Autoimmune dysfunction and subsequent renal insufficiency in a collegiate female athlete: a case report. Colandreo, RM; Kern, A; Leone, JE; Williamson, JD, )	0.13
" The proposed approach was successfully applied to the analysis of pharmaceutical dosage forms with good accuracy and precision."	( A novel analytical approach for reducing the consumption of organic solvents in the charge transfer-based spectrophotometric analysis: application in the analysis of certain antihypertensive drugs. Al-Majed, AR; Darwish, IA; Mahmoud, AM, 2010)	0.36
"To detect clinical predictors of renal worsening in CHF patient population characterized by two types of ACE-inhibitor dosing regimens."	( ACE-inhibitor therapy at relatively high doses and risk of renal worsening in chronic heart failure. Ariano, C; Cantatrione, S; Ciccarelli, A; Cioppa, C; De Vecchis, R; Di Biase, G; Giasi, A; Pucciarelli, A, 2011)	0.37
" After screening 184 haemodialysis patients, 14 fulfilled the inclusion criteria, mainly long-term use of oral lisinopril in the upper end of dosage range for this population with stable haemoglobin levels and intravenous ESA therapy."	( Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. Brunner, M; Herkner, H; Hörl, WH; Kletzmayr, J; Prehslauer, A; Sengoelge, G; Sunder-Plassmann, G; Winnicki, W, 2012)	0.38
" An additional aim is to assess the effect of the polypill on LDL-c and BP compared to the administration of separate pills of identically dosed components of the polypill."	( The evening versus morning polypill utilization study: the TEMPUS rationale and design. Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R, 2014)	0.4
"5 mg) in the evening; (2) the polypill in the morning; and (3) the use of the identically dosed agents in separate pills taken at different time points during the day."	( The evening versus morning polypill utilization study: the TEMPUS rationale and design. Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R, 2014)	0.4
"A simple and rapid stability-indicating liquid chromatographic method was developed and validated for the simultaneous determination of lisinopril and hydrochlorotiazide (HCTZ) in drug substances and dosage forms in the presence of degradation products."	( Stability-indicating LC method for the simultaneous determination of lisinopril and hydrochlorothiazide. de Diego, M; Mennickent, S; Soto, J, )	0.13
"Studies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP) reduction."	( Time of administration important? Morning versus evening dosing of valsartan. Crikelair, N; Kandra, A; Palatini, P; Zappe, DH, 2015)	0.42
" Evening dosing also did not improve BP lowering in patients requiring add-on HCTZ or in nondippers at baseline."	( Time of administration important? Morning versus evening dosing of valsartan. Crikelair, N; Kandra, A; Palatini, P; Zappe, DH, 2015)	0.42
"Once-daily dosing of valsartan 320 mg results in equally effective 24-h BP efficacy, regardless of dosing time."	( Time of administration important? Morning versus evening dosing of valsartan. Crikelair, N; Kandra, A; Palatini, P; Zappe, DH, 2015)	0.42
" The floating bilayer tablets of lisinopril maleate and metoprolol tartrate were designed to overcome the various problems associated with conventional oral dosage form."	( Formulation and in-vitro evaluation of floating bilayer tablet of lisinopril maleate and metoprolol tartrate. Abdel-Daim, M; Danish, Z; Hanif, M; Ijaz, H; Mohammad, IS; Qureshi, J; Waheed, I; Zaman, M, 2015)	0.42
" Group III was co-treated with GAR at a therapeutic dosage of 250 mg/kg body weight per day."	( Garlic capsule and selenium-vitamins ACE combination therapy modulate key antioxidant proteins and cellular adenosine triphosphate in lisinopril-induced lung damage in rats. Akintunde, DG; Akintunde, JK; Bolarin, OE, 2016)	0.43
" Twice-daily lisinopril dosing was associated with greater systolic blood pressure reductions compared with the same total daily dose administered once daily."	( Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension. Dai, IY; Kroehl, ME; Smith, SM; Thompson, AM; Trinkley, KE; Tsai, T, 2017)	0.46
"The contemporary work describes a rapid and cost effective reversed phase High Performance Liquid Chromatography (RP-HPLC) method for the quantification of Captopril, Lisinopril and Dexibuprofen (DXP) simultaneously in dosage formulations, active pharmaceutical ingredients and human serum."	( Simultaneous determination of ACE inhibitors and dexibuprofen in active pharmaceutical ingredient, formulations and human serum by RP-HPLC. Naveed, S; Qamar, F; Sana, A; Shakeel, S, 2017)	0.46
" Furthermore, the developed procedure was adapted for studying the content uniformity test of some dosage forms containing the cited drug."	( An innovative validated spectrofluorimetric method for determination of Lisinopril in presence of hydrochlorothiazide; application to content uniformity testing. Badr El-Din, KM; Derayea, SM; Mohammed, FF, 2018)	0.48
" History was remarkable only for a doubling of her Lisinopril dosage 2 months prior to the appearance of her lesions, with no other potential environmental and/or drug triggers recognizable on history taking."	( Lisinopril-associated bullous pemphigoid in an elderly woman: a case report of a rare adverse drug reaction. Ballout, RA; Khattar, J; Musharrafieh, U, 2018)	0.48
" In the absence of AH, patients received scheme I -(Mertenil® at initial dosage of 10 mg/day)."	( ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk. Ansheles, AA; Boytsov, SA; Drapkina, ОМ; Gornyakova, NB; Kuharchuk, VV; Sergienko, IV; Shepel, RN; Zubareva, MY, 2019)	0.51
" A major barrier to entry of this technology is the lack of non-destructive quality control methods capable of verifying the dosage of multiple drugs in polyprintlets at the point of dispensing."	( Non-destructive dose verification of two drugs within 3D printed polyprintlets. Basit, AW; Gaisford, S; Goyanes, A; Rowland, M; Tan, HX; Trenfield, SJ; Wilsdon, D, 2020)	0.56
"Lisinopril and losartan manufacturer labels recommend twice-daily dosing (BID) if once-daily (QDay) is insufficient to lower blood pressure (BP)."	( Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. Botts, SR; Delate, T; Derington, CG; Kao, DP; King, JB; Kroehl, M; Trinkley, KE, 2020)	0.56
" Propensity scores were generated, and differences in BP and adverse events (angioedema, acute kidney injury, hyperkalemia) between BID/QDay groups were analyzed within dosing cohorts using inverse propensity of treatment-weighted regression models."	( Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. Botts, SR; Delate, T; Derington, CG; Kao, DP; King, JB; Kroehl, M; Trinkley, KE, 2020)	0.56
"4 with the evening dosing (р<0."	( Psychological Continuum of Elderly Patients Suffering from Arterial Hypertension with Metabolic Syndrome, Against the Background of Chronotherapy with a Fixed Combination of Amlodipine, Lisinopril and Rosuvastatin. Agarkov, NM; Kolomiets, VI; Korneeva, SI; Markelova, AM; Markelova, EA; Moskalev, AA; Moskaleva, EO; Okhotnikov, OI, 2021)	0.62
" The applied method demonstrated the precise dosage opportunities of the inkjet printing methodology for customization and drug waste reduction."	( Technical evaluation of precisely manufacturing customized microneedle array patches via inkjet drug printing. Breitkreutz, J; Lammerding, LC, 2023)	0.91

Role	Description
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	An EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
dipeptide	Any molecule that contains two amino-acid residues connected by peptide linkages.
hydrate	An addition compound that contains water in weak chemical combination with another compound.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Renin-angiotensin pathway (COVID-19 Disease Map)	1	16

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	33.4915	0.0060	38.0041	19,952.5996	AID1159521
USP1 protein, partial	Homo sapiens (human)	Potency	39.8107	0.0316	37.5844	354.8130	AID504865
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	7.9433	0.0013	18.0743	39.8107	AID926
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	7.9433	0.2512	15.8432	39.8107	AID504327
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0010	0.8913	12.0676	28.1838	AID1487
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	11.2202	0.0096	10.5250	35.4813	AID1479145
TDP1 protein	Homo sapiens (human)	Potency	4.6109	0.0008	11.3822	44.6684	AID686978
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	10.0000	0.0355	20.9770	89.1251	AID504332
chromobox protein homolog 1	Homo sapiens (human)	Potency	100.0000	0.0060	26.1688	89.1251	AID540317
Vpr	Human immunodeficiency virus 1	Potency	1.5849	1.5849	19.6264	63.0957	AID651644
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Angiotensin-converting enzyme	Homo sapiens (human)	IC50 (µMol)	0.0021	0.0001	0.5336	10.0000	AID1503699; AID1895844; AID39018; AID39616; AID39622; AID39767; AID39769; AID780572
Angiotensin-converting enzyme	Homo sapiens (human)	Ki	0.0640	0.0000	0.8255	7.5000	AID1819416; AID1819417; AID271448; AID271449; AID271475
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	0.2870	0.0000	1.6129	10.0000	AID1168279; AID1231572; AID763534
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	Ki	0.0510	0.0004	2.0337	8.6606	AID271474
Type-2 angiotensin II receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0012	0.0010	0.3957	3.3000	AID39622
Angiotensin-converting enzyme	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0012	0.0009	0.3322	3.0300	AID39616
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, BCL-2-RELATED PROTEIN A1	Homo sapiens (human)	EC50 (µMol)	350.0000	8.0570	121.1218	338.0000	AID2765
bcl-2-like protein 11 isoform 1	Homo sapiens (human)	EC50 (µMol)	350.0000	8.0570	121.1218	338.0000	AID2765
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to hypoxia	Angiotensin-converting enzyme	Homo sapiens (human)
kidney development	Angiotensin-converting enzyme	Homo sapiens (human)
blood vessel remodeling	Angiotensin-converting enzyme	Homo sapiens (human)
angiotensin maturation	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of renal output by angiotensin	Angiotensin-converting enzyme	Homo sapiens (human)
neutrophil mediated immunity	Angiotensin-converting enzyme	Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class I	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensin	Angiotensin-converting enzyme	Homo sapiens (human)
proteolysis	Angiotensin-converting enzyme	Homo sapiens (human)
spermatogenesis	Angiotensin-converting enzyme	Homo sapiens (human)
female pregnancy	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of blood pressure	Angiotensin-converting enzyme	Homo sapiens (human)
male gonad development	Angiotensin-converting enzyme	Homo sapiens (human)
response to xenobiotic stimulus	Angiotensin-converting enzyme	Homo sapiens (human)
embryo development ending in birth or egg hatching	Angiotensin-converting enzyme	Homo sapiens (human)
post-transcriptional regulation of gene expression	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of gene expression	Angiotensin-converting enzyme	Homo sapiens (human)
substance P catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
bradykinin catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of smooth muscle cell migration	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of vasoconstriction	Angiotensin-converting enzyme	Homo sapiens (human)
animal organ regeneration	Angiotensin-converting enzyme	Homo sapiens (human)
response to nutrient levels	Angiotensin-converting enzyme	Homo sapiens (human)
response to lipopolysaccharide	Angiotensin-converting enzyme	Homo sapiens (human)
mononuclear cell proliferation	Angiotensin-converting enzyme	Homo sapiens (human)
response to laminar fluid shear stress	Angiotensin-converting enzyme	Homo sapiens (human)
angiotensin-activated signaling pathway	Angiotensin-converting enzyme	Homo sapiens (human)
vasoconstriction	Angiotensin-converting enzyme	Homo sapiens (human)
hormone metabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
hormone catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
eating behavior	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of apoptotic process	Angiotensin-converting enzyme	Homo sapiens (human)
peptide catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of vasoconstriction	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of glucose import	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of synaptic plasticity	Angiotensin-converting enzyme	Homo sapiens (human)
lung alveolus development	Angiotensin-converting enzyme	Homo sapiens (human)
amyloid-beta metabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
arachidonic acid secretion	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of neurogenesis	Angiotensin-converting enzyme	Homo sapiens (human)
heart contraction	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of angiotensin metabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
hematopoietic stem cell differentiation	Angiotensin-converting enzyme	Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesis	Angiotensin-converting enzyme	Homo sapiens (human)
cellular response to glucose stimulus	Angiotensin-converting enzyme	Homo sapiens (human)
response to dexamethasone	Angiotensin-converting enzyme	Homo sapiens (human)
cell proliferation in bone marrow	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of calcium ion import	Angiotensin-converting enzyme	Homo sapiens (human)
response to thyroid hormone	Angiotensin-converting enzyme	Homo sapiens (human)
blood vessel diameter maintenance	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of hematopoietic stem cell proliferation	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of gap junction assembly	Angiotensin-converting enzyme	Homo sapiens (human)
cellular response to aldosterone	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylation	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Angiotensin-converting enzyme	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
endopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
carboxypeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
metalloendopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
calmodulin binding	Angiotensin-converting enzyme	Homo sapiens (human)
peptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
metallopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
exopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
tripeptidyl-peptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
peptidyl-dipeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
zinc ion binding	Angiotensin-converting enzyme	Homo sapiens (human)
chloride ion binding	Angiotensin-converting enzyme	Homo sapiens (human)
mitogen-activated protein kinase kinase binding	Angiotensin-converting enzyme	Homo sapiens (human)
bradykinin receptor binding	Angiotensin-converting enzyme	Homo sapiens (human)
mitogen-activated protein kinase binding	Angiotensin-converting enzyme	Homo sapiens (human)
metallodipeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
heterocyclic compound binding	Angiotensin-converting enzyme	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme	Homo sapiens (human)
extracellular region	Angiotensin-converting enzyme	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme	Homo sapiens (human)
lysosome	Angiotensin-converting enzyme	Homo sapiens (human)
endosome	Angiotensin-converting enzyme	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
external side of plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
basal plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
brush border membrane	Angiotensin-converting enzyme	Homo sapiens (human)
extracellular exosome	Angiotensin-converting enzyme	Homo sapiens (human)
sperm midpiece	Angiotensin-converting enzyme	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1409614	Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID271476	Selectivity for rabbit testis ACE C domain over human ACE N domain	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1409608	AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1676602	Binding affinity to ferric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID271451	Selectivity for ACE C domain over ACE N domain	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1676599	Binding affinity to cupric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID481439	Absolute bioavailability in human	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID763534	Inhibition of rabbit lung ACE assessed as hydrolysis of hippuryl-histidyl-leucine to hippuric acid and histidyl-leucine after 30 mins	2013	Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15	Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID592681	Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID679611	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 uM, Lisinopril: 50 uM) in MDR1-expressing LLC-PK1 cells	2002	Life sciences, Feb-15, Volume: 70, Issue:13	Interaction of digoxin with antihypertensive drugs via MDR1.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID681152	TP_TRANSPORTER: uptake in Xenopus laevis oocytes	2002	Drug metabolism and pharmacokinetics, , Volume: 17, Issue:4	Transporter-mediated Drug Interactions.
AID1503699	Inhibition of ACE (unknown origin) using Hippuryl-L-Histidyl-L-Leucine as substrate after 60 mins by colorimetric method	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Therapeutic investigations of novel indoxyl-based indolines: A drug target validation and Structure-Activity Relationship of angiotensin-converting enzyme inhibitors with cardiovascular regulation and thrombolytic potential.
AID1895844	Inhibition of angiotensin converting enzyme (unknown origin)	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Zinc enzymes in medicinal chemistry.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID481440	Dissociation constant, pKa of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1676589	Binding affinity to Nickel cation assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID39769	Inhibitory activity against Angiotensin I converting enzyme (ACE) from human blood serum	2003	Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15	Computer-aided selection of potential antihypertensive compounds with dual mechanism of action.
AID1676600	Binding affinity to zinc ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID481444	Octanol-water partition coefficient, log P of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1676598	Binding affinity to cupric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID404304	Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID39767	Inhibitory activity against angiotensin I converting enzyme (ACE)	2000	Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3	Protease inhibitors: current status and future prospects.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1676592	Binding affinity to Gallium ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1676591	Binding affinity to Nickel cation assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1676588	Binding affinity to Zinc ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID481441	Aqueous diffusivity at 37C	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1409607	IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1156815	Inhibition of rabbit lung ACE assessed as inhibition of hippuryl-histidyl-leucine substrate hydrolysis at 1 uM pretreated for 10 mins followed by addition of 5 mM HHL substrate for 30 mins measured as hippuric acid release	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Design and green synthesis of 2-(diarylalkyl)aminobenzothiazole derivatives and their dual activities as angiotensin converting enzyme inhibitors and calcium channel blockers.
AID780572	Inhibition of human serum ACE	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Perindopril and ramipril phosphonate analogues as a new class of angiotensin converting enzyme inhibitors.
AID481442	Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID271448	Inhibition of testis ACE C domain	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme.
AID1409609	Cytotoxicity of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1676594	Binding affinity to gallium ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID38846	Compound tested in vitro for inhibition of Angiotensin I converting enzyme in rat	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Angiotensin converting enzyme inhibitors: spirapril and related compounds.
AID481446	Effective permeability across human jejunum	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID271449	Inhibition of somatic ACE N domain	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme.
AID1676590	Binding affinity to Nickel cation assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1819416	Inhibition of recombinant human ACE C-domain expressed in CHO cells using Cbz-Phe-His-Leu as substrate preincubated for 15 mins followed by substrate addition and measured after 10 mins by fluorescence spectrophotometric analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1409613	Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID25867	Ratio of biliary and urinary excretion of angiotensin converting enzyme inhibitors in male rat after intravenous dosing.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID445446	Oral bioavailability in human	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID26306	Logarithm of the ratio of anionic to unionized species at pH 7.4	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats.
AID1676595	Binding affinity to Ferric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1409611	AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID39616	Inhibition of Angiotensin I converting enzyme	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Excursions in drug discovery.
AID26526	Compound was tested for its maximum lipophilicity.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats.
AID445445	Permeability at pH 6.5 by PAMPA method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID39018	Inhibitory activity against angiotensin converting enzyme (ACE)	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and com
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID763533	Cytotoxicity against human A549 cells assessed as cell survival after 24 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15	Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors.
AID1819417	Inhibition of recombinant human ACE N-domain expressed in CHO cells using Cbz-Phe-His-Leu as substrate preincubated for 15 mins followed by substrate addition and measured after 10 mins by fluorescence spectrophotometric analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition.
AID763532	Cytotoxicity against HEK293 cells assessed as cell survival after 24 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15	Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1676593	Binding affinity to Gallium ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1503700	Inhibition of ACE (unknown origin) at IC50 using Hippuryl-L-Histidyl-L-Leucine as substrate after 60 mins by colorimetric method relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Therapeutic investigations of novel indoxyl-based indolines: A drug target validation and Structure-Activity Relationship of angiotensin-converting enzyme inhibitors with cardiovascular regulation and thrombolytic potential.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID271475	Inhibition of recombinant ACE N domain	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1607330	Selectivity index, ratio of Ki for human wild type ACE N-domain to Ki for human testis ACE C-domain (unknown origin) using Abz-FRK(Dnp)P-OH as substrate by fluorescence based analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1676596	Binding affinity to Ferric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1819415	Selectivity ratio of Ki for human ACE N-domain expressed in CHO cells to Ki for human ACE C-domain expressed in CHO cells	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition.
AID1168279	Inhibition of rabbit lung ACE using hippuryl-histidyl-leucine as substrate assessed as release of hippuric acid incubated for 10 mins prior to substrate addition measured after 30 mins by spectrophotometry	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Synthesis and evaluation of novel triazoles and mannich bases functionalized 1,4-dihydropyridine as angiotensin converting enzyme (ACE) inhibitors.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1676597	Binding affinity to cupric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID25873	The acid dissociation constant, pKa was determined. a'' represents value of C-terminus carboxylic acid.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats.
AID1676601	Binding affinity to Zinc ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID271474	Inhibition of rabbit testis recombinant ACE C domain	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID39622	Inhibition of Angiotensin I converting enzyme (ACE) in Bothrops jararaca venom	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1231572	Inhibition of rabbit lung ACE assessed as hippuryl-histidyl-leucine hydrolysis after 30 mins by colorimetric method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345457	Human Angiotensin-converting enzyme (M2: Angiotensin-converting (ACE and ACE2))	1997	Molecular pharmacology, Jun, Volume: 51, Issue:6	Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	145 (7.01)	18.7374
1990's	691 (33.40)	18.2507
2000's	669 (32.33)	29.6817
2010's	454 (21.94)	24.3611
2020's	110 (5.32)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	648 (29.32%)	5.53%
Trials	0 (0.00%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	124 (5.61%)	6.00%
Reviews	0 (0.00%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	285 (12.90%)	4.05%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	9 (0.41%)	0.25%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	1,144 (51.76%)	84.16%
Other	12 (100.00%)	84.16%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (115)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria [NCT03201939]	Phase 2	280 participants (Anticipated)	Interventional	2024-02-29	Suspended(stopped due to DSMB recommendations--lab QC issues relate to urine albumin measurement (>2-year pause). DSMB approval obtained (3/24/2023) to re-open but will not enroll participants until new/separate funding obtained as this award ends in Feb. 2024.)
Series of Single Patient Trials Comparing the Efficacy Between the Most Commonly Prescribed Thiazide Diuretic in the US, Hydrochlorothiazide, and Lisinopril for the Treatment of Stage 1 Hypertension. [NCT01258764]		2 participants (Actual)	Interventional	2010-11-30	Completed
Evaluation of Perioperative Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preoperative Hypertension [NCT02441842]	Phase 4	85 participants (Actual)	Interventional	2006-03-31	Completed
A Randomized Clinical Trial of the N-of-1 Approach in Children With Hypertension [NCT03461003]	Phase 4	49 participants (Actual)	Interventional	2018-04-02	Completed
Randomized, Open-label, Three Treatment Crossover Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study [NCT01380431]	Phase 1	18 participants (Actual)	Interventional	1999-08-31	Completed
Safety and Efficacy of Maximally Tolerated RAAS Blockade and Spironolactone Therapy on Urinary Proteinuria and Progression of Type II Diabetic Nephropathy in African Americans and Other Patient Cohorts. [NCT03502031]	Phase 4	72 participants (Anticipated)	Interventional	2018-10-01	Recruiting
Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence, Implication of Type of Anesthesia and Identification of Other Etiological Factors [NCT03967496]		402 participants (Actual)	Observational [Patient Registry]	2019-01-01	Completed
An Open-label, Single Arm, Sequential, Single Centre Trial Investigating the Influence of Oral Semaglutide (NNC0113-0217) on Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects [NCT02070510]	Phase 1	52 participants (Actual)	Interventional	2014-02-27	Completed
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects [NCT02232308]	Phase 1	24 participants (Actual)	Interventional	2014-07-31	Completed
Dose Titration Study to Test Efficacy and Safety of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension. [NCT02184858]	Phase 4	13 participants (Actual)	Interventional	2014-06-25	Completed
Bioequivalence Study of Compound Lisinopril Tablets [NCT04885660]	Phase 1	92 participants (Actual)	Interventional	2018-10-12	Completed
A Non-randomized, Open-label, Single-dose, Crossover Study to Evaluate the Dose Proportionality of the Final Fixed Dose Combination Formulation of COREG CR™ and Lisinopril. [NCT00549510]	Phase 1	29 participants (Actual)	Interventional	2007-10-31	Completed
A Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2, Dose-finding Study With ACT-132577 in Subjects With Essential Hypertension (Grade 1 and 2). [NCT02603809]	Phase 2	1,659 participants (Actual)	Interventional	2015-12-14	Completed
Randomized, Open-label, Two-treatment Crossover, of a 10 mg Single Oral Dose, Study to Compare the Lisinopril Plasma Levels Produced After Administration of the Test Formulation With Those Produced After Administration of a Marketed Reference Product, Zes [NCT01375244]	Phase 1	36 participants (Actual)	Interventional	1999-06-30	Completed
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease (KXK005). [NCT01101269]		6 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to Slow Recruitment)
A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia [NCT05056727]	Phase 3	1,500 participants (Anticipated)	Interventional	2021-09-30	Recruiting
PITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies [NCT01126697]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2010-02-28	Completed
The Chymase Angiotensin-(1-12) Axis in Hypertensive Disease [NCT05644769]	Phase 4	10 participants (Anticipated)	Interventional	2022-11-15	Recruiting
A Pilot, Prospective, Randomized, Open-label, Blinded Endpoint (Probe) Histopathology Trial to Assess the Effects of ACE- Inhibition Therapy on Glomerular Proliferative Lesions in Patients With Extracapillary Glomerulonephritis [NCT02682459]	Phase 2	22 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM) [NCT02847338]	Phase 4	1,320 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Lisinopril To Reduce Microalbuminuria In Postpartum Preeclamptic Women. A Role For Renal Protection? [NCT05016440]		0 participants (Actual)	Interventional	2015-09-30	Withdrawn
Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study. [NCT03392740]	Phase 4	200 participants (Anticipated)	Interventional	2018-03-15	Not yet recruiting
A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Sy [NCT00391846]	Phase 4	252 participants (Actual)	Interventional	2006-10-31	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
The Precision Hypertension Care Study [NCT02774460]	Phase 4	280 participants (Actual)	Interventional	2017-02-20	Completed
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study) [NCT00555217]	Phase 3	1,448 participants (Actual)	Interventional	2008-07-31	Terminated(stopped due to It was stopped primarily because of safety concerns along with low conditional power to detect a treatment effect on the primary outcome.)
A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied Drug/Drug Interaction (DDI) Probe Compounds [NCT02641899]	Phase 1	33 participants (Actual)	Interventional	2015-12-31	Completed
COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects With Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either Carvedilol CR + Lisinopril o [NCT00624065]	Phase 3	348 participants (Actual)	Interventional	2008-03-31	Completed
Genetic Mechanisms in Human Hypertension RAAS Inhibition Study [NCT01009944]		0 participants (Actual)	Interventional	2007-01-31	Withdrawn(stopped due to Not funded.)
A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination With and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Re [NCT00108082]	Phase 3	287 participants (Actual)	Interventional	2005-01-31	Completed
Randomized Study of Antihypertensives and Antilipemics in American Indians With Non-Insulin-Dependent Diabetes Mellitus at High Risk of Developing Nephropathy and Cardiovascular Disease [NCT00004266]	Phase 3	160 participants (Actual)	Interventional	1993-08-31	Completed
A Randomised, Placebo-controlled Pilot Trial to Examine the Efficacy of Interventions to Prevent Left Ventricular Remodelling in Patients Receiving New Pacemaker Implantation (OPT-Prevent-pilot). [NCT03422705]	Phase 2	75 participants (Anticipated)	Interventional	2022-12-01	Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Nebivolol Added To Antihypertensive Treatment With Lisinopril or Losartan in Patients With Hypertension. [NCT00734630]	Phase 4	491 participants (Actual)	Interventional	2008-08-31	Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]	Phase 4	21,983 participants (Actual)	Interventional	2008-09-01	Completed
Hypertension in Hemodialysis Patients [NCT00582114]	Phase 3	200 participants (Actual)	Interventional	2005-08-31	Terminated(stopped due to Stopped by data safety monitoring board)
Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up [NCT00171574]	Phase 4	124 participants (Actual)	Interventional	2004-11-30	Completed
NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial [NCT02817360]	Phase 4	2,400 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI:Effects on Oxidative Stress and Inflammation. [NCT00430040]	Phase 4	14 participants (Actual)	Interventional	2007-02-28	Terminated
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Aleglitazar 150 µg in Type 2 Diabetic Patients Treated With Lisinopril 20 mg on Renal Function, the Renin-angiotensin System and the Pharmacokinetics of Lis [NCT01398267]	Phase 1	55 participants (Actual)	Interventional	2011-08-31	Completed
Randomized, 2-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions. [NCT00883064]	Phase 1	32 participants (Actual)	Interventional	2000-03-31	Completed
Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease [NCT00874432]	Phase 2	43 participants (Actual)	Interventional	2009-01-31	Completed
Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose [NCT00673790]	Phase 4	537 participants (Actual)	Interventional	2008-05-15	Completed
Aliskiren and Renin Inhibition in Diastolic Heart Failure in Mexican Americans [NCT00773084]		0 participants (Actual)	Interventional	2008-09-30	Withdrawn(stopped due to Difficulty in recruiting patients and then the PI left the institution)
Women With Chest Pain and Normal Coronary Arteries Study: A Randomized Study of Medical Treatment and Therapeutic Lifestyle Changes [NCT00743197]		3 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Terminated due to departure of PI from institution.)
Renal Denervation in Patients After Acute Coronary Syndrome [NCT01901549]	Phase 2	80 participants (Anticipated)	Interventional	2013-06-30	Recruiting
Bioequivalence Study of 10 mg Lisinopril Tablets (Lisinopril 10 mg) Produced by PT Dexa Medica in Comparison With The Innovator Tablets (Zestril® 10 mg, PT Boehringer Ingelheim Indonesia, Indonesia, Under License From Astra Zeneca UK Ltd.) [NCT01936012]		34 participants (Actual)	Interventional	2013-02-28	Completed
Randomized, 3-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions Under Fasting and Fed Conditions. [NCT00883506]	Phase 1	24 participants (Actual)	Interventional	2000-05-31	Completed
Comparative, Open Multicenter Trial Assessing the Effect on Albumin Excretion Rate of 320mg Valsartan (With or Without HCTZ) vs 40mg Lisinopril (With or Without HCTZ) on Hypertensive Patients With Diabetic and Non-diabetic Nephropathy and Albuminuria [NCT00171600]	Phase 4	54 participants (Actual)	Interventional	2005-07-31	Terminated
A Randomized, Double-blind, Parallel-Group Study to Evaluate the Effects of First-Line Treatment With a Free Combination of Nebivolol and Lisinopril Compared With Placebo and the Monotherapy Components on Blood Pressure in Patients With Stage 2 Diastolic [NCT01218100]	Phase 4	664 participants (Actual)	Interventional	2010-10-31	Completed
The Vascular Effects of Carvedilol Controlle Release (CR) + Lisinopril Versus Lisinopril + Hydrochlorothiazide (HCTZ) in Abdominally Obese Hypertensive Patients [NCT00459056]	Phase 3	25 participants (Actual)	Interventional	2007-04-30	Completed
Comparative Blood Pressure Effects of Nebivolol Versus Lisinopril in Patients With New Onset or Exacerbated Hypertension Induced by Bevacizumab: a Crossover Study [NCT01076140]		0 participants (Actual)	Interventional	2010-02-28	Withdrawn(stopped due to No participants enrolled)
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment With 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40m [NCT00347360]	Phase 3	654 participants (Actual)	Interventional	2006-07-31	Completed
A Randomized, Open-label, Single-dose, Crossover Study to Demonstrate the Bioequivalence of the Final Fixed Dose Combination (FDC) Formulation (COREG CR & Lisinopril) to COREG CR & ZESTRIL Employed in the Phase III Factorial Study [NCT00552708]	Phase 1	55 participants (Actual)	Interventional	2007-09-30	Completed
Paramedic Initiated Lisinopril For Acute Stroke Treatment: a Pilot Randomised Controlled Trial [NCT01066572]	Phase 1	14 participants (Actual)	Interventional	2010-10-31	Completed
HALT Progression of Polycystic Kidney Disease Study A [NCT00283686]	Phase 3	558 participants (Actual)	Interventional	2006-01-31	Completed
The Usefulness of Non-invasive Assessment of Haemodynamic Profile in the Diagnosis and Treatment of Hypertension [NCT01996085]		144 participants (Actual)	Interventional	2013-01-31	Completed
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment [NCT00006294]		37,939 participants (Actual)	Observational	1999-09-30	Completed
Pharmacokinetic and Pharmacodynamic Effect of LY2189265 on Lisinopril in Subjects With Hypertension and Metoprolol in Healthy Subjects [NCT01324388]	Phase 1	51 participants (Actual)	Interventional	2011-03-31	Completed
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD [NCT04550481]	Phase 2	45 participants (Anticipated)	Interventional	2021-04-01	Recruiting
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]	Phase 3	10,251 participants (Actual)	Interventional	1999-09-30	Completed
The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors in Resistant Hypertension [NCT02623036]	Phase 1	20 participants (Anticipated)	Interventional	2015-11-30	Recruiting
Lack of Effect of Antihypertensive Treatment With Amlodipine and Lisinopril on Retinal Autoregulation in Patients With Type 1 Diabetes and Mild Diabetic Retinopathy. A Prospective Randomized Clinical Trial. [NCT00337298]		25 participants (Actual)	Interventional	2006-07-31	Completed
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patient [NCT00123903]	Phase 3	1,220 participants	Interventional	2005-07-31	Terminated
Optimal Dose of ACE Inhibitor for Treatment of Diabetic Nephropathy in Type 1 Diabetic Patients With Hypertension and Diabetic Nephropathy [NCT00118976]		60 participants	Interventional	2005-03-31	Completed
A Study to Evaluate the Potential Incidence of Orthostatic Hypotension in Elderly Hypertensive Patients Following Administration of a Combination of COREG CR and Lisinopril [NCT00508365]	Phase 1	62 participants (Actual)	Interventional	2007-09-25	Completed
A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin, Griseofulvin and Digoxin, and Liraglutide's Potential [NCT01518166]	Phase 1	70 participants (Actual)	Interventional	2006-05-31	Completed
Compare Efficacy of the Angiotensin Converting Enzyme Inhibitor (ACEi) Lisinopril With Angiotensin II Receptor Antagonist Losartan (ARB) for the Cardiomyopathy of Duchenne Muscular Dystrophy [NCT01982695]		23 participants (Actual)	Interventional	2009-03-31	Completed
Cognitive and Cerebrovascular Sequelae of Hypertension [NCT00151138]		50 participants	Interventional	2002-09-30	Completed
A Study to Evaluate the Effectiveness of Valsartan 320 mg in Combination With Lisinopril 20 mg Versus Monotherapy With Lisinopril 40 mg or Valsartan 320 mg in Hypertensive Patients With Microalbuminuria on the Reduction of Urinary Albumin Creatinine Ratio [NCT00171067]	Phase 3	134 participants (Actual)	Interventional	2004-07-31	Completed
Clinical Bioequivalence Study on Two Lisinopril Tablets 20mg Formulations [NCT03599466]	Phase 1	30 participants (Anticipated)	Interventional	2019-10-31	Not yet recruiting
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease. DETECT (DEtection and Treatment of Early Cardiovascular Disease Trial) [NCT00553969]	Phase 1/Phase 2	101 participants (Actual)	Interventional	2007-11-30	Completed
Novel Therapies for Resistant Focal Segmental Glomerulosclerosis [NCT00814255]	Phase 2	32 participants (Actual)	Interventional	2008-12-31	Completed
A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India With Zestoretic® 20/25 Lis [NCT01831700]	Phase 1	48 participants (Actual)	Interventional	2012-10-31	Completed
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study [NCT01669434]	Phase 4	291 participants (Actual)	Interventional	2015-06-01	Completed
A Randomized, Double Blind, Double Dummy, Parallel Group, Active-Controlled Study To Evaluate The Effectiveness Of Morning Versus Evening Doses Of 320 Mg Valsartan Versus 40 Mg Lisinopril On The 24 Hour Blood Pressure Profile In Patients With Hypertension [NCT00241124]	Phase 4	1,099 participants (Actual)	Interventional	2004-04-30	Completed
Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria [NCT00280215]	Phase 3	0 participants (Actual)	Interventional	2007-12-31	Withdrawn(stopped due to Inadequate number of patients, lack of funding)
Black Education and Treatment of Hypertension (BEAT HTN) [NCT00661895]	Phase 4	99 participants (Actual)	Interventional	2005-08-31	Completed
Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study). [NCT00295542]	Phase 4	3,344 participants (Actual)	Interventional	2000-03-31	Completed
HALT Progression of Polycystic Kidney Disease Study B [NCT01885559]	Phase 3	486 participants (Actual)	Interventional	2006-01-31	Completed
[NCT00311870]	Phase 4	52 participants	Interventional	1993-03-31	Completed
A Randomised Controlled Cross-over Trial to Evaluate Evening Versus Morning Administration of a Cardiovascular Polypill [NCT01506505]		78 participants (Actual)	Interventional	2012-07-31	Completed
A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril® (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under [NCT01735318]	Phase 1	40 participants (Actual)	Interventional	2012-06-30	Completed
A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril® (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under [NCT01735344]	Phase 1	40 participants (Actual)	Interventional	2012-06-30	Completed
Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. [NCT04662723]	Phase 4	878 participants (Anticipated)	Interventional	2023-05-01	Recruiting
A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India With Zestoretic® 20/25 Lis [NCT01827878]	Phase 1	48 participants (Actual)	Interventional	2012-10-31	Completed
A Phase II Study of the Effect of ACE Inhibitors on Pro-Angiogenic Hormones in Cancer Patients With Hypertension [NCT01234922]	Phase 2	6 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to slow accrual)
Is There a Benefit to Optimize HF (Heart Failure) Treatment in Aged Over 80 Year's Old Patients? [NCT01437371]	Phase 3	35 participants (Actual)	Interventional	2011-08-31	Completed
Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study [NCT00982189]		37 participants (Actual)	Interventional	2009-09-30	Completed
Effect of Polipill on Patients at High Cardiovascular Risk : a Randomized Controlled Trial [NCT01313702]	Phase 3	0 participants (Actual)	Interventional	2012-10-31	Withdrawn
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]	Phase 4	2,414 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR) Trial [NCT04190433]	Phase 2	0 participants (Actual)	Interventional	2020-09-01	Withdrawn(stopped due to Administratively closed due to low/no accrual)
A Randomized, Open-label Study to Evaluate the Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release, Alone and in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide, in Chin [NCT02336607]		529 participants (Actual)	Interventional	2005-12-31	Completed
Effects of Angiotensin Converting Enzyme Inhibitors on Peritoneal Protein Loss and Solute Transport in Peritoneal Dialysis Patients [NCT01575652]	Phase 4	43 participants (Actual)	Interventional	2008-06-30	Completed
Randomized Crossover 2 Period Single Dose Bioequivalence Study of 2 Formulations Lisinopril Tab. 20mg (Pharmtechnology LLC,Belarus) and Zestril® Tab. 20mg (Avara Reims Pharmaceutical Services, France) in Healthy Volunteers Under Fasting Conditions [NCT05061901]	Phase 1	38 participants (Actual)	Interventional	2021-10-06	Completed
[NCT00000542]	Phase 3	0 participants	Interventional	1993-08-31	Completed
CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX) [NCT01984164]	Phase 2	176 participants (Actual)	Interventional	2014-08-20	Completed
Optimization of Pre-surgical Testing With an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events in Orthopedic Surgery [NCT01837069]	Phase 4	198 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Low recruitment / DSMB approval to halt recruitment)
A Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLE [NCT04486118]	Phase 2	36 participants (Anticipated)	Interventional	2021-10-01	Recruiting
A Randomized Placebo Controlled Trial of Low Dose Angiotensin Converting Enzyme Inhibitor to Prevent Pneumonia in Older People Who Require Tube Feeding Because of Neurological Dysphagia [NCT02358642]	Phase 4	93 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to The interim analysis suggested that low dose lisinopril given to be tube fed older patients with neuroligical dysphagia had increased mortality.)
Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) [NCT03195023]	Phase 4	106 participants (Anticipated)	Interventional	2015-06-30	Recruiting
A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer [NCT05530655]	Early Phase 1	70 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients [NCT01491919]	Phase 1	26 participants (Actual)	Interventional	2012-06-30	Completed
Reducing Total Cardiovascular Risk in an Urban Community [NCT00241904]	Phase 4	525 participants (Actual)	Interventional	2006-05-31	Completed
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension [NCT01658657]		17 participants (Actual)	Interventional	2012-10-31	Completed
A Double-Blind Pilot Study to Measure the Effect of Lisinopril vs. Placebo on Pulmonary Distress in Patients Receiving External Beam Radiotherapy to the Lung [NCT01880528]	Phase 2	23 participants (Actual)	Interventional	2013-05-31	Completed
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study [NCT01691781]		41 participants (Actual)	Interventional	2012-10-31	Completed
ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study [NCT01535235]	Phase 4	31 participants (Actual)	Interventional	2012-02-29	Completed
Radiofrequency Ablation for Atrial Fibrillation in Advanced Chronic Heart Failure [NCT00292162]		41 participants (Actual)	Interventional	2007-01-31	Completed
Phase II Placebo-controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy With Trastuzumab (Herceptin®) [NCT01009918]	Phase 2	468 participants (Actual)	Interventional	2010-03-31	Completed
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial) [NCT00605072]	Phase 2	53 participants (Actual)	Interventional	2008-01-31	Completed
A Randomized, Open-label, Single-dose, 3-period Crossover Study to Assess the Effect of Food on the Pharmacokinetics of the Final Fixed Dose Combination Formulation of COREG CR and Lisinopril in the Fed and Fasted State. [NCT00557128]	Phase 1	24 participants (Actual)	Interventional	2007-11-30	Completed
A 5-year Prospective, Placebo-controlled, Crossover Evaluation of the Efficacy and Tolerability of Low-dose Lisinopril in Normotensives With Idiopathic Oligospermic Infertility [NCT01409837]	Phase 2	33 participants (Actual)	Interventional	1998-03-31	Completed
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD [NCT03417388]	Phase 4	4,422 participants (Anticipated)	Interventional	2018-02-09	Recruiting
Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension [NCT02412761]		42 participants (Actual)	Interventional	2013-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00000620 (6) [back to overview]	Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]	Stroke in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00108082 (14) [back to overview]	Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12
NCT00108082 (14) [back to overview]	Mean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12
NCT00108082 (14) [back to overview]	Model-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12
NCT00108082 (14) [back to overview]	Percentage Change From Baseline in Log Transformed Lipid Parameters at Month 12
NCT00241904 (4) [back to overview]	Systolic Blood Pressure
NCT00241904 (4) [back to overview]	Patients' Satisfaction With Care and Health Care Utilization
NCT00241904 (4) [back to overview]	Low-density Lipoprotein Cholesterol
NCT00241904 (4) [back to overview]	HbA1c
NCT00283686 (9) [back to overview]	All-Cause Hospitalizations
NCT00283686 (9) [back to overview]	Kidney Function (eGFR)
NCT00283686 (9) [back to overview]	Left Ventricular Mass Index
NCT00283686 (9) [back to overview]	Quality of Life Physical Component Summary
NCT00283686 (9) [back to overview]	Renal Blood Flow
NCT00283686 (9) [back to overview]	Study A: Percent Annual Change in Total Kidney Volume
NCT00283686 (9) [back to overview]	Aldosterone
NCT00283686 (9) [back to overview]	Albuminuria
NCT00283686 (9) [back to overview]	Quality of Life Mental Component Summary
NCT00292162 (6) [back to overview]	Plasma B-type Natriuretic Peptide (BNP) at Baseline
NCT00292162 (6) [back to overview]	Plasma B-type Natriuretic Peptide (BNP) at 6 Months
NCT00292162 (6) [back to overview]	Plasma B-type Natriuretic Peptide (BNP)
NCT00292162 (6) [back to overview]	Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%
NCT00292162 (6) [back to overview]	Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)
NCT00292162 (6) [back to overview]	Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months
NCT00347360 (11) [back to overview]	Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure
NCT00347360 (11) [back to overview]	Change From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure
NCT00347360 (11) [back to overview]	Change From Baseline to Week 6 in Trough Diastolic Blood Pressure
NCT00347360 (11) [back to overview]	Change From Baseline to Week 6 in Trough Systolic Blood Pressure
NCT00347360 (11) [back to overview]	Change From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring)
NCT00347360 (11) [back to overview]	Diastolic Responders, Defined as ≥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of <90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures)
NCT00347360 (11) [back to overview]	Change From Baseline to Week 6 in Mean SBP and DBP Measured at Night by 24hr ABPM
NCT00347360 (11) [back to overview]	Change From Baseline to Week 6 in Mean Trough Sitting SBP and Sitting DBP by Cuff Assessment
NCT00347360 (11) [back to overview]	Change From Baseline to Week 6 in Mean SBP and DBP Measured in Morning by 24 Hour ABPM
NCT00347360 (11) [back to overview]	Dose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring)
NCT00347360 (11) [back to overview]	Change From Baseline to Week 6 in Mean SBP and DBP Measured in Afternoon by 24hr ABPM
NCT00391846 (8) [back to overview]	Changes in Health-related Quality of Life
NCT00391846 (8) [back to overview]	Changes in Heart Failure Symptoms
NCT00391846 (8) [back to overview]	Changes in NT-proBNP Values Over Time in All Patients
NCT00391846 (8) [back to overview]	Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)
NCT00391846 (8) [back to overview]	Discontinuations
NCT00391846 (8) [back to overview]	Number of CV Deaths
NCT00391846 (8) [back to overview]	Number of Days in Hospital for CV Reason
NCT00391846 (8) [back to overview]	Total Number of Titration Steps in Prescribed Heart Failure Treatment
NCT00459056 (1) [back to overview]	Change in Reactive Hyperemic Index by Period (Carvedilol CR + Lisinopril vs. Lisinopril + HCTZ)
NCT00553969 (1) [back to overview]	Change in Disease Score (DS) Among the Treatment Groups
NCT00555217 (2) [back to overview]	A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD.
NCT00555217 (2) [back to overview]	A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73mm in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73mm, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death
NCT00582114 (2) [back to overview]	Serious Adverse Events and Cardiovascular Events That Led to Trial Termination
NCT00582114 (2) [back to overview]	The Primary End Point is the Regression of Left Ventricular Hypertrophy (LVH) by Echocardiographic Criteria From Baseline to 1 Year.
NCT00605072 (5) [back to overview]	Cognitive Assessment: Trail Making Test Part B
NCT00605072 (5) [back to overview]	Blood Flow Velocity, Sitting
NCT00605072 (5) [back to overview]	Blood Pressure Outcome: Systolic BP
NCT00605072 (5) [back to overview]	Cognitive Assessment: Forward Digit Span Test
NCT00605072 (5) [back to overview]	Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall
NCT00624065 (2) [back to overview]	Mean Change From Baseline in Sitting Systolic Blood Pressure (sSBP) and Sitting Diastolic Blood Pressure (sDBP) at Week 6
NCT00624065 (2) [back to overview]	Number of Participants With Mean Sitting Cuff Blood Pressure <140/90 mmHg at the End of 6 Weeks of Treatment
NCT00661895 (1) [back to overview]	Percentage of Subjects Achieving Blood Pressure Goals
NCT00673790 (2) [back to overview]	Plasma Glucose Level After an Oral Glucose Tolerance Test
NCT00673790 (2) [back to overview]	Trough Seated Diastolic Blood Pressure
NCT00734630 (2) [back to overview]	Mean Seated Trough Cuff Diastolic Blood Pressure (DBP) at Week 12
NCT00734630 (2) [back to overview]	Mean Seated Trough Cuff Systolic Blood Pressure (SBP) at Week 12
NCT00814255 (2) [back to overview]	Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those With an Initial Value Above 90 OR Within 25% of Baseline for Remaining Patients
NCT00814255 (2) [back to overview]	Number of Participants With Adverse Events
NCT00874432 (2) [back to overview]	Mean Vascular Stiffness As Measured by PWV
NCT00874432 (2) [back to overview]	Aortic Pulse Wave Velocity (PWV)
NCT00982189 (9) [back to overview]	Changes in Blood Pressure
NCT00982189 (9) [back to overview]	Changes in Small Artery Elasticity
NCT00982189 (9) [back to overview]	Changes IL-6 (Interleukin-6)
NCT00982189 (9) [back to overview]	Changes hsCRP (C-reactive Protein)
NCT00982189 (9) [back to overview]	Number of Participants Who Stated (by Self-report) That They Had Side Effects
NCT00982189 (9) [back to overview]	Change From Baseline to Month 4 in the Framingham Risk Score (FRS)
NCT00982189 (9) [back to overview]	Changes in Blood Lipids
NCT00982189 (9) [back to overview]	Number of Participants Who Took >90% of Their Doses (by Pill Count)
NCT00982189 (9) [back to overview]	Changes TNFa (Tumor Necrosis Factor Alpha)
NCT01009918 (5) [back to overview]	Quality-of-life Changes Between Baseline and 52-weeks
NCT01009918 (5) [back to overview]	Number of Participants With Cardiotoxicity-free Survival at 750 Days From Baseline
NCT01009918 (5) [back to overview]	Number of Participants With LVEF Decrease to <50%
NCT01009918 (5) [back to overview]	Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment
NCT01009918 (5) [back to overview]	Number of Patients With Trastuzumab Course Interruption
NCT01218100 (2) [back to overview]	The Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6.
NCT01218100 (2) [back to overview]	The Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6.
NCT01234922 (1) [back to overview]	Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter
NCT01324388 (8) [back to overview]	Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Lisinopril
NCT01324388 (8) [back to overview]	Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol
NCT01324388 (8) [back to overview]	Mean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Lisinopril
NCT01324388 (8) [back to overview]	Mean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol
NCT01324388 (8) [back to overview]	Pharmacokinetics, Area Under the Concentration Curve (AUC) of Metoprolol When Administered With LY2189265
NCT01324388 (8) [back to overview]	Pharmacokinetics, Maximum Concentration (Cmax) of Lisinopril
NCT01324388 (8) [back to overview]	Pharmacokinetics, Maximum Concentration (Cmax) of Metoprolol When Administered With LY2189265
NCT01324388 (8) [back to overview]	Pharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril
NCT01409837 (9) [back to overview]	Adverse Events Monitoring
NCT01409837 (9) [back to overview]	Changes From Baseline in the Seminal Fluid Characteristics Throughout the Study
NCT01409837 (9) [back to overview]	Ejaculate Volume
NCT01409837 (9) [back to overview]	Proportion of Sperm Cells With Abnormal Morphology (%)
NCT01409837 (9) [back to overview]	Proportion of Sperm Cells With Abnormal Morphology (%)
NCT01409837 (9) [back to overview]	Proportion of Sperm Cells With Normal Motility (%)
NCT01409837 (9) [back to overview]	Proportion of Sperm Cells With Normal Motility (%)
NCT01409837 (9) [back to overview]	Total Sperm Cell Count
NCT01409837 (9) [back to overview]	Total Sperm Cell Count Per Milliliter of Seminal Fluid.
NCT01491919 (14) [back to overview]	PK - Maximum Observed Concentration of Drug in Plasma (Cmax)
NCT01491919 (14) [back to overview]	PK - Oral Clearance (CL/F)
NCT01491919 (14) [back to overview]	PK - Time of the Maximum Observed Concentration in Plasma (Tmax)
NCT01491919 (14) [back to overview]	PK Renal Clearance (CLrenal)
NCT01491919 (14) [back to overview]	Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group
NCT01491919 (14) [back to overview]	Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants
NCT01491919 (14) [back to overview]	Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group
NCT01491919 (14) [back to overview]	Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants
NCT01491919 (14) [back to overview]	Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration
NCT01491919 (14) [back to overview]	Worse Post-dose Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline in Lisinopril-naive Participants
NCT01491919 (14) [back to overview]	Change in Potassium Level From Baseline in Lisinopril-naive Participants
NCT01491919 (14) [back to overview]	Change in Urine Protein/Creatinine From Baseline in Lisinopril-naive Participants.
NCT01491919 (14) [back to overview]	Largest eGFR Percent Decrease From Baseline in Lisinopril-naive Participants
NCT01491919 (14) [back to overview]	Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC)
NCT01535235 (2) [back to overview]	Change in HIV DNA (Copies/Million Rectal Cells)
NCT01535235 (2) [back to overview]	Change in HIV RNA (Copies/Million Rectal Cells)
NCT01658657 (1) [back to overview]	Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic
NCT01669434 (6) [back to overview]	Postoperative Hypotension
NCT01669434 (6) [back to overview]	Low Blood Pressure Subgroup
NCT01669434 (6) [back to overview]	Acute Renal Failure
NCT01669434 (6) [back to overview]	Postoperative Hypertension
NCT01669434 (6) [back to overview]	Older Age Subgroup
NCT01669434 (6) [back to overview]	Number of Participants With Interoperative Hypotension
NCT01691781 (3) [back to overview]	Urinary Aldosterone Excretion Measurements Following 1 Week of ACE Inhibitor Therapy
NCT01691781 (3) [back to overview]	Serum Calcium Following 1 Week of ACE Inhibitor Administration
NCT01691781 (3) [back to overview]	Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration
NCT01837069 (2) [back to overview]	Length of Stay
NCT01837069 (2) [back to overview]	Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism
NCT01880528 (5) [back to overview]	Acute Respiratory Distress (Dyspnea), Measured Using of the Maximum Score, at Any Time, of the Shortness of Breath Question (Item #4) on the LCSS (Worst Dyspnea Score)
NCT01880528 (5) [back to overview]	Experience Shortness of Breath During Exercise as Measured Using Item #3 on the Symptom Experience Questionnaire (SEQ) at Week 4
NCT01880528 (5) [back to overview]	Incidence of Grade 3 or Higher Hypotension, Acute Kidney Injury, Allergic Reaction, or Anaphylaxis, as Measured Using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0
NCT01880528 (5) [back to overview]	Quality of Life (Dyspnea When Climbing Stairs) Assessed Using Item #5 of the European Organization for Research on the Treatment of Cancer Lung Cancer Module Survey (EORTC-QLQ-LC13) at Week 4
NCT01880528 (5) [back to overview]	Total LCSS Score as Measure by the Lung Cancer Symptom Scale (LCSS) at Week 4
NCT01885559 (8) [back to overview]	Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.
NCT01885559 (8) [back to overview]	Quality of Life Mental Component Summary
NCT01885559 (8) [back to overview]	Quality of Life Physical Component Summary
NCT01885559 (8) [back to overview]	Albuminuria
NCT01885559 (8) [back to overview]	Aldosterone
NCT01885559 (8) [back to overview]	Back or Flank Pain
NCT01885559 (8) [back to overview]	Cardiovascular Hospitalizations
NCT01885559 (8) [back to overview]	Hospitalizations
NCT01982695 (1) [back to overview]	Cardiac Ejection Fraction as Measured by Echocardiogram
NCT01984164 (8) [back to overview]	Executive Function
NCT01984164 (8) [back to overview]	Language
NCT01984164 (8) [back to overview]	Memory
NCT01984164 (8) [back to overview]	White Matter Lesion Volume
NCT01984164 (8) [back to overview]	Cerebral Perfusion
NCT01984164 (8) [back to overview]	"NINDS-initiated EXecutive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research or EXAMINER Tool Box."
NCT01984164 (8) [back to overview]	Attention Measured Using Digit Span Backward
NCT01984164 (8) [back to overview]	Attention Measured Using Digit Span Forward
NCT02336607 (12) [back to overview]	The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 2 Weeks of Felodipine Sustained Release, Alone
NCT02336607 (12) [back to overview]	The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]	The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]	The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]	The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]	The Magnitude of Systolic and Diastolic Blood Pressure Change From Baseline Among All Randomized Subjects After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]	The Change of Pulse Wave Velocity From Baseline at 2, 14 Weeks of Felodipine Sustained Release Alone.
NCT02336607 (12) [back to overview]	The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]	The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]	The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]	The Change of Pulse Wave Velocity at 12 Weeks Compare With Baseline Data of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]	The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02412761 (1) [back to overview]	The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy
NCT02603809 (8) [back to overview]	Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Diastolic Blood Pressure
NCT02603809 (8) [back to overview]	Ratio of Group Mean at Trough to Group Mean at Peak for Diastolic Blood Pressure Based on Ambulatory Blood Pressure Monitoring (ABPM)
NCT02603809 (8) [back to overview]	Change From Baseline to End of Double-blind Treatment in Sitting Systolic Blood Pressure at Trough
NCT02603809 (8) [back to overview]	Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough
NCT02603809 (8) [back to overview]	Change From Baseline to End of Double-blind Treatment in 24-hour Diastolic and Systolic Ambulatory Blood Pressure Monitoring (ABPM)
NCT02603809 (8) [back to overview]	Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Systolic Blood Pressure
NCT02603809 (8) [back to overview]	Control Rates at the End of the Double-blind Treatment Period Based on Trough Sitting Diastolic and Systolic Blood Pressure
NCT02603809 (8) [back to overview]	Supportive Analysis of Primary Endpoint: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough
NCT03461003 (5) [back to overview]	Number of Participants Who Self-reported Adherence to Intervention
NCT03461003 (5) [back to overview]	Patient Satisfaction With Intervention as Assessed by a Survey
NCT03461003 (5) [back to overview]	Change in Mean 24-hour Ambulatory Systolic Blood Pressure
NCT03461003 (5) [back to overview]	Change in Mean Wake Ambulatory Systolic Blood Pressure
NCT03461003 (5) [back to overview]	Number of Participants Who Reported That Side Effects From Medication Led Them to Discontinue Medication

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Intervention	participants (Number)
Glycemia Trial: Intensive Control	391
Glycemia Trial: Standard Control	327

Intervention	milliliters (mL) (Mean)
	LV E-volume	LV A-volume
Atenolol	6.763	-0.565
Carvedilol CR	0.364	-0.513
Lisinopril	-3.406	1.088

Intervention	milliliters (mL) (Mean)
	LV End Systolic Volume	LV End Diastolic Volume	LV Ejection Fraction
Atenolol	-4.74	-3.64	2.33
Carvedilol CR	-3.38	-3.07	1.03
Lisinopril	-5.34	-9.37	0.63

Intervention	mmHg (millimeters of mercury) (Mean)
	Systolic blood pressure	Diastolic blood pressure
Atenolol	-21.12	-14.05
Carvedilol CR	-21.32	-12.77
Lisinopril	-22.53	-11.13

Intervention	percentage of change (Geometric Mean)
	Total cholesterol	Low-density lipid cholesterol	High-density lipid cholesterol	Triglycerides
Atenolol	-1.3	-4.0	-4.7	7.1
Carvedilol CR	0.7	0.0	-4.3	11.0
Lisinopril	-1.7	-2.7	-1.5	6.2

Intervention	mmHg (Mean)
Comprehensive Intervention Group	130.8
Less Intensive Intervention Group	135.9

Intervention	mg/dL (Mean)
Comprehensive Intervention Group	100.1
Less Intensive Intervention Group	110.6

Intervention	events (Number)
ACE-I + ARB	85
ACE-I Alone	128
Low Blood Pressure Group	93
Standard Blood Pressure Group	120

Intervention	ml/min/1.73/m2/yr (Mean)
ACE-I + ARB	-3.0
ACE-I Alone	-2.9
Low Blood Pressure Group	-2.9
Standard Blood Pressure Group	-3.0

Intervention	annual change in g/m^2 (Mean)
ACE-I + ARB	-0.91
ACE-I Alone	-0.83
Low Blood Pressure Group	-1.17
Standard Blood Pressure Group	-0.57

Intervention	annual change in units on a scale (Mean)
ACE-I + ARB	-0.24
ACE-I Alone	-.23
Low Blood Pressure Group	-0.17
Standard Blood Pressure Group	-0.30

Intervention	g/m raised to 2.7 (g/(m^2.7)) (Mean)
Carvedilol CR	-11.78
Atenolol	-12.51
Lisinopril	-11.61

Intervention	grams (g) (Mean)
Carvedilol CR	-13.74
Atenolol	-14.17
Lisinopril	-17.17

Intervention	grams per meters squared (g/m^2) (Mean)
Carvedilol CR	-20.35
Atenolol	-20.06
Lisinopril	-18.48

Intervention	grams per meters squared (g/m^2) (Mean)
Carvedilol CR	-6.34
Atenolol	-6.67
Lisinopril	-7.94

Intervention	annual change in mL/min/1.73 m^2 (Mean)
ACE-I + ARB	-6.6
ACE-I Alone	-9.5
Low Blood Pressure Group	-7.6
Standard Blood Pressure Group	-8.5

Intervention	annual percent change in mg/24 hr (Mean)
ACE-I + ARB	-1.1
ACE-I Alone	-0.4
Low Blood Pressure Group	-3.8
Standard Blood Pressure Group	2.4

Intervention	annual change in units on a scale (Mean)
ACE-I + ARB	0.19
ACE-I Alone	-0.06
Low Blood Pressure Group	-0.05
Standard Blood Pressure Group	0.18

Intervention	mmHg (Mean)
Lisinopril 10	-5.79
Lisinopril 20	-8.11
Lisinopril 40	-7.37
Carvedilol Controlled Release 20	-4.40
Carvedilol Controlled Release 40	-7.61
Carvedilol Controlled Release 80	-6.52
Carvedilol Controlled Release 20 Lisinopril 10	-9.29
Carvedilol Controlled Release 20 Lisinopril 20	-8.57
Carvedilol Controlled Release 20 Lisinopril 40	-10.19
Carvedilol Controlled Release 40 Lisinopril 10	-9.36
Carvedilol Controlled Release 40 Lisinopril 20	-10.96
Carvedilol Controlled Release 40 Lisinopril 40	-10.37
Carvedilol Controlled Release 80 Lisinopril 10	-10.93
Carvedilol Controlled Release 80 Lisinopril 20	-11.09
Carvedilol Controlled Release 80 Lisinopril 40	-11.92

Intervention	mmHg (Mean)
Lisinopril 10	-9.19
Lisinopril 20	-13.58
Lisinopril 40	-10.60
Carvedilol Controlled Release 20	-6.15
Carvedilol Controlled Release 40	-9.84
Carvedilol Controlled Release 80	-10.38
Carvedilol Controlled Release 20 Lisinopril 10	-12.06
Carvedilol Controlled Release 20 Lisinopril 20	-11.58
Carvedilol Controlled Release 20 Lisinopril 40	-14.16
Carvedilol Controlled Release 40 Lisinopril 10	-11.68
Carvedilol Controlled Release 40 Lisinopril 20	-14.03
Carvedilol Controlled Release 40 Lisinopril 40	-13.90
Carvedilol Controlled Release 80 Lisinopril 10	-15.60
Carvedilol Controlled Release 80 Lisinopril 20	-15.93
Carvedilol Controlled Release 80 Lisinopril 40	-15.59

Intervention	mmHg (Mean)
Lisinopril 10	-6.40
Lisinopril 20	-6.08
Lisinopril 40	-8.16
Carvedilol Controlled Release 20	-2.34
Carvedilol Controlled Release 40	-7.76
Carvedilol Controlled Release 80	-5.26
Carvedilol Controlled Release 20 Lisinopril 10	-5.14
Carvedilol Controlled Release 20 Lisinopril 20	-6.36
Carvedilol Controlled Release 20 Lisinopril 40	-7.22
Carvedilol Controlled Release 40 Lisinopril 10	-6.79
Carvedilol Controlled Release 40 Lisinopril 20	-7.76
Carvedilol Controlled Release 40 Lisinopril 40	-4.90
Carvedilol Controlled Release 80 Lisinopril 10	-6.54
Carvedilol Controlled Release 80 Lisinopril 20	-7.26
Carvedilol Controlled Release 80 Lisinopril 40	-8.42

Intervention	mmHg (Mean)
Lisinopril 10	-9.47
Lisinopril 20	-7.52
Lisinopril 40	-9.54
Carvedilol Controlled Release 20	-0.96
Carvedilol Controlled Release 40	-9.27
Carvedilol Controlled Release 80	-5.68
Carvedilol Controlled Release 20 Lisinopril 10	-6.44
Carvedilol Controlled Release 20 Lisinopril 20	-9.27
Carvedilol Controlled Release 20 Lisinopril 40	-9.88
Carvedilol Controlled Release 40 Lisinopril 10	-8.87
Carvedilol Controlled Release 40 Lisinopril 20	-8.11
Carvedilol Controlled Release 40 Lisinopril 40	-5.82
Carvedilol Controlled Release 80 Lisinopril 10	-9.80
Carvedilol Controlled Release 80 Lisinopril 20	-10.74
Carvedilol Controlled Release 80 Lisinopril 40	-10.00

Intervention	trough:peak ratio x 100% (Number)
Lisinopril 10	133.33
Lisinopril 20	61.04
Lisinopril 40	114.45
Carvedilol Controlled Release 20	34.11
Carvedilol Controlled Release 40	71.00
Carvedilol Controlled Release 80	49.67
Carvedilol Controlled Release 20 Lisinopril 10	44.50
Carvedilol Controlled Release 20 Lisinopril 20	49.46
Carvedilol Controlled Release 20 Lisinopril 40	59.47
Carvedilol Controlled Release 40 Lisinopril 10	54.71
Carvedilol Controlled Release 40 Lisinopril 20	52.86
Carvedilol Controlled Release 40 Lisinopril 40	37.93
Carvedilol Controlled Release 80 Lisinopril 10	41.95
Carvedilol Controlled Release 80 Lisinopril 20	53.54
Carvedilol Controlled Release 80 Lisinopril 40	52.07

Intervention	mmHg (Mean)
	Change in Night SBP from Baseline to Week 6	Change in Night DBP from Baseline to Week 6
Carvedilol Controlled Release 20	-4.28	-3.20
Carvedilol Controlled Release 20 Lisinopril 10	-10.37	-8.11
Carvedilol Controlled Release 20 Lisinopril 20	-9.94	-7.03
Carvedilol Controlled Release 20 Lisinopril 40	-12.64	-9.36
Carvedilol Controlled Release 40	-7.70	-6.49
Carvedilol Controlled Release 40 Lisinopril 10	-10.02	-8.23
Carvedilol Controlled Release 40 Lisinopril 20	-11.87	-9.34
Carvedilol Controlled Release 40 Lisinopril 40	-11.25	-9.09
Carvedilol Controlled Release 80	-7.71	-5.34
Carvedilol Controlled Release 80 Lisinopril 10	-12.08	-8.27
Carvedilol Controlled Release 80 Lisinopril 20	-14.12	-9.88
Carvedilol Controlled Release 80 Lisinopril 40	-13.06	-10.14
Lisinopril 10	-9.01	-5.83
Lisinopril 20	-11.58	-6.78
Lisinopril 40	-10.38	-7.49

Intervention	mmHg (Mean)
	Change in sSBP by Cuff from Baseline to Week 6	Change in sDBP by Cuff from Baseline to Week 6
Carvedilol Controlled Release 20	-5.68	-6.87
Carvedilol Controlled Release 20 Lisinopril 10	-9.54	-5.66
Carvedilol Controlled Release 20 Lisinopril 20	-11.84	-10.02
Carvedilol Controlled Release 20 Lisinopril 40	-13.43	-10.28
Carvedilol Controlled Release 40	-5.07	-5.70
Carvedilol Controlled Release 40 Lisinopril 10	-9.79	-8.73
Carvedilol Controlled Release 40 Lisinopril 20	-11.26	-10.89
Carvedilol Controlled Release 40 Lisinopril 40	-13.49	-9.63
Carvedilol Controlled Release 80	-8.88	-7.54
Carvedilol Controlled Release 80 Lisinopril 10	-6.42	-8.22
Carvedilol Controlled Release 80 Lisinopril 20	-9.00	-9.45
Carvedilol Controlled Release 80 Lisinopril 40	-14.58	-10.95
Lisinopril 10	-11.97	-7.45
Lisinopril 20	-10.85	-5.32
Lisinopril 40	-13.09	-10.35

lisinopril

Description

Cross-References

Synonyms (273)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (2)

Pathways (1)

Protein Targets (21)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (96)

Molecular Functions (40)

Ceullar Components (24)

Bioassays (205)

Research

Studies (2,069)

Market Indicators

Research Demand Index: 137.41

Study Types

Clinical Trials (115)

Trial Overview

Trial Outcomes

Death From Any Cause in the Glycemia Trial.

Stroke in the Blood Pressure Trial.

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12

Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12

Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12

Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12

Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12

Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12

Mean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12

Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12

Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12

Model-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12

Percentage Change From Baseline in Log Transformed Lipid Parameters at Month 12

Systolic Blood Pressure

Patients' Satisfaction With Care and Health Care Utilization

Low-density Lipoprotein Cholesterol

HbA1c

All-Cause Hospitalizations

Kidney Function (eGFR)

Left Ventricular Mass Index

Quality of Life Physical Component Summary

Renal Blood Flow

Study A: Percent Annual Change in Total Kidney Volume

Aldosterone

Albuminuria

Quality of Life Mental Component Summary

Plasma B-type Natriuretic Peptide (BNP) at Baseline

Plasma B-type Natriuretic Peptide (BNP) at 6 Months

Plasma B-type Natriuretic Peptide (BNP)

Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%

Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)

Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months

Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure

Change From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure

Change From Baseline to Week 6 in Trough Diastolic Blood Pressure

Change From Baseline to Week 6 in Trough Systolic Blood Pressure

Change From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring)

Diastolic Responders, Defined as ≥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of <90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures)

Change From Baseline to Week 6 in Mean SBP and DBP Measured at Night by 24hr ABPM

Change From Baseline to Week 6 in Mean Trough Sitting SBP and Sitting DBP by Cuff Assessment

Change From Baseline to Week 6 in Mean SBP and DBP Measured in Morning by 24 Hour ABPM

Dose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring)

Change From Baseline to Week 6 in Mean SBP and DBP Measured in Afternoon by 24hr ABPM

Changes in Health-related Quality of Life

A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73mm in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73mm, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death

Intervention	mmHg (Mean)
	Change in Morning SBP from Baseline to Week 6	Change in Morning DBP from Baseline to Week 6
Carvedilol Controlled Release 20	-6.23	-5.01
Carvedilol Controlled Release 20 Lisinopril 10	-13.89	-9.21
Carvedilol Controlled Release 20 Lisinopril 20	-10.22	-7.86
Carvedilol Controlled Release 20 Lisinopril 40	-14.50	-10.04
Carvedilol Controlled Release 40	-10.42	-6.82
Carvedilol Controlled Release 40 Lisinopril 10	-12.78	-8.79
Carvedilol Controlled Release 40 Lisinopril 20	-14.29	-11.15
Carvedilol Controlled Release 40 Lisinopril 40	-14.84	-9.96
Carvedilol Controlled Release 80	-13.70	-7.53
Carvedilol Controlled Release 80 Lisinopril 10	-17.09	-11.95
Carvedilol Controlled Release 80 Lisinopril 20	-14.52	-10.71
Carvedilol Controlled Release 80 Lisinopril 40	-17.12	-12.46
Lisinopril 10	-9.37	-6.12
Lisinopril 20	-14.53	-9.20
Lisinopril 40	-10.76	-7.62

Intervention	mmHg (Mean)
Lisinopril 10	-5.77
Lisinopril 20	-7.55
Lisinopril 40	-7.49
Carvedilol Controlled Release 20	-5.11
Carvedilol Controlled Release 40	-6.61
Carvedilol Controlled Release 80	-7.13
Carvedilol Controlled Release 20 Lisinopril 10	-8.08
Carvedilol Controlled Release 20 Lisinopril 20	-9.83
Carvedilol Controlled Release 20 Lisinopril 40	-9.71
Carvedilol Controlled Release 40 Lisinopril 10	-9.55
Carvedilol Controlled Release 40 Lisinopril 20	-11.3
Carvedilol Controlled Release 40 Lisinopril 40	-11.1
Carvedilol Controlled Release 80 Lisinopril 10	-10.0
Carvedilol Controlled Release 80 Lisinopril 20	-11.7
Carvedilol Controlled Release 80 Lisinopril 40	-11.4

Intervention	mmHg (Mean)
	Change in Afternoon SBP from Baseline to Week 6	Change in Afternoon DBP from Baseline to Week 6
Carvedilol Controlled Release 20	-9.69	-6.27
Carvedilol Controlled Release 20 Lisinopril 10	-13.96	-11.28
Carvedilol Controlled Release 20 Lisinopril 20	-15.54	-12.04
Carvedilol Controlled Release 20 Lisinopril 40	-16.38	-11.59
Carvedilol Controlled Release 40	-13.34	-10.12
Carvedilol Controlled Release 40 Lisinopril 10	-14.51	-12.18
Carvedilol Controlled Release 40 Lisinopril 20	-17.97	-14.03
Carvedilol Controlled Release 40 Lisinopril 40	-17.82	-12.54
Carvedilol Controlled Release 80	-13.76	-8.38
Carvedilol Controlled Release 80 Lisinopril 10	-20.91	-15.12
Carvedilol Controlled Release 80 Lisinopril 20	-20.46	-13.87
Carvedilol Controlled Release 80 Lisinopril 40	-19.36	-15.02
Lisinopril 10	-9.68	-5.62
Lisinopril 20	-17.21	-10.25
Lisinopril 40	-10.53	-6.67

Intervention	Ratio (Mean)
Carvedilol CR + Lisinopril, Then Lisinopril +HCTZ	-0.26
Lisinopril + HCTZ, Then Carvedilol CR + Lisinopril	-0.14

Intervention	Overall Rasmussen Disease Score Change (Mean)
1 Coreg CR + Lisinopril	-2.48
2 Coreg CR + Placebo	-2.29
3 Lisinopril + Placebo	-2.38
4 Placebo + Placebo	-0.96

Intervention	events/100 patient-years (Number)
	Incidence rate, cardiovasular events	Incidence rate, combined MI, stroke, CHF, CV death	Incidence rate, congest heart failure	Incidence rate, all-cause hospitalizations
Atenolol	24.6	13.5	6.2	89.9
Lisinopril	58	31	20.2	144.3

Intervention	g/m^2 (Mean)
	LVMI Change from baseline, 6 months	LVMI Change from baseline, 12 months
Atenolol	-8.4	-21.5
Lisinopril	-3.4	-15.1

Intervention	mmHg (Mean)
	sSBP (mmHg)	sDBP (mmHg)
Carvedilol CR + Lisinopril	-16.07	-9.14
Lisinopril	-17.05	-10.15

Intervention	Participants (Number)
	Responders (mean BP <140/90 mmHg)	Non-responders (SBP >/=140 mmHg or DBP >/=90 mmHg)
Carvedilol CR + Lisinopril	137	64
Lisinopril	139	64

Intervention	participants (Number)
Conservative Medical Therapy Plus Adalimumab	0
Conservative Medical Therapy (Lisinopril, Losartan, Atorvastat	2
Conservative Medical Therapy Plus Galactose	2